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ABSTRACT 
Background  And  Objective: Pseudomonas  aeruginosa  infections  are  becoming  
an  important  cause  of  morbidity  in  hospitalized  patients. The  increasing  
resistance  of  P.aeruginosa  to  various  antibiotics  mainly  carbapenems  is  
becoming  an  important  concern. Emergence of  Metallobetalactamase   producing 
organisms is alarming and reflects the excessive use of carbapenems . The present 
study was conducted at our hospital with an aim to know the prevalence of 
Carbapenem resistance  and  production of metallo-betalactamases  by  four  different 
phenotypic methods. 
Methodology: A  total  of  211 P. aeruginosa isolates from various clinical samples 
were tested. Antibiotic sensitivity testing was carried out by Kirby- Bauer method 
according to CLSI guidelines and detection of Metallobetalactamase production was 
carried out by Meropenem - EDTA combined disc method, Double  Disc  Synergy  
Test, Modified Hodge test and  E  test.   
Results: Among  the  isolates males  were  more  commonly  affected  in  the  above  
40  years  age  group and  the  isolates  were  obtained  from  inpatients  frequently. 
Pus  swab  is  the predominant specimen  obtained  mostly  from  surgery  ward. 
Cellulitis  is  the  most  observed  infection. The resistance pattern to various 
antibiotics were- Amikacin (32.23%), Gentamycin (36.02%), Tobramycin (35.07%), 
Ceftazidime (71.09%),Ciprofloxacin(46.45%), Cefaperazone+sulbactum(35.07%), 
Cefipime(29.86%), Piperacillin+tazobactum (18.96%), Aztreonam(23.22%), 
Meropenem(7.58%);in  urine  isolates, Ofloxacin (23.8%), Norfloxacin (71.43%), 
Nitrofurantoin (80.95%). Among  Meropenem  resistant  isolates, 93.75% were 
positive for Metallobetalactamase production  detected  by  E  test.  Only 81.25%  of  
MBL  were  detected  by  Combined  Disc Test(CDT)  and  Double Disc Synergy Test 
(DDST), 75%  were  detected by Modified  Hodge  Test(MHT).  E  test method for 
MBL detection was found to have a sensitivity, specificity, positive predictive value, 
negative predictive value and accuracy of 100 %, 100%, 100%, 100% and 100%. 
Conclusion, Significance and Impact of study: E test method  is  a  simple and 
reliable method for metallobetalactamase detection which can be used routinely in 
any laboratory. DDST and  CDT are almost equally effective and more sensitive than 
MHT for detection of  MBL production  in  small  laboratories  which  can’t  afford  E 
test. Thus routine screening for MBL mediated carbapenem resistance coupled  with  
strict  infection  control practices is critical  to  prevent  the consequences  of  this  
worrying  resistance  mechanisms and to ensure appropriate treatment of infections 
caused by them in clinical settings. 
Keywords- Pseudomonas aeruginosa, Metallobetalactamases, E test. 
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                                         INTRODUCTION 
            
                                       Pseudomonas  aeruginosa  is  an  aerobic  Gram  
negative  bacillus,  motile  by  a  single  flagella  and  it  is  frequently  seen  
in  moist  environment.  P. aeruginosa  commonly  cause  nosocomial  
infection  occurring  mostly  in  surgical  wards  and  intensive  care  units 
.Persons  with  intact  host  defences  are  not  at  risk  to   get  severe  P. 
aeruginosa  infection  but  the  neutropenic  patients ( like  patients  
receiving cancer  chemotherapy)  suffer  increased  risk   for   invasive  
infections.  Although  it  can  affect  normal  individuals,  it  is  becoming  a  
major  threat  to  immunocompromised  and  hospitalized  patients,  
particularly  in  those  suffering  from  cancer  and  burns.  The  high  
mortality  due  to  this  infection  is  associated  with  bacterial  resistance  to  
antibiotics impaired  host  defense  system.  
                                         As  this  bacteria  is  resistant  to  routinely  used  
antimicrobial  agents,  it  causes  a  big  clinical  problem  and  a  major  
public  health  threat.  The  other  important  issue  is  that  there  are  only  a  
few  antimicrobial  agents  including  the  antipseudomonal penicillins, 
cephalosporins,  aminoglycosides,  carbapenems,  and  fluoroquinolones  
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with  reliable  activity  against  it. Antimicrobial  resistance  in  P.aeruginosa  
is  both  intrinsic1  and  acquired.  Acquired  resistance:  It  may  be  due  to  
either  chromosomal  or  plasmid  mediated  β  lactamases   ( eg.  Penicillins 
and  cephalosporins,  occasionally  carbapenems  and  aztreonam ),  DNA  
gyrase  mutation ( eg. Fluoroquinolones )  or  decreased  outer  membrane  
permeability  through  porin  loss ( eg. Carbapenems )  and  aminoglycoside  
inactivating  enzymes2.  Because  of  increasing  use  of  carbapenems  in  
organisms  producing  ESBLs, now carbapenem  resistant  Pseudomonas  
aeruginosa  are  emerging  and  it leads  to  treatment  failure  even  if  
combined  drugs  are  being  used.                  
                   There  are  different  mechanisms  for  carbapenem  resistance  
such  as  1)   loss  of  outer  membrane  proteins, 2)   mutation  in  porins  
leading  to  lack  of drug  penetration  and  3)   up-regulation  of  efflux  
systems.            
                  The  important  mechanism  of  microbial  resistance  is  by  
hydrolysis  of  betalactam  antibiotics  by  betalactamase  enzymes.  
Responding  to  the  high  pressure  of  antibiotic  use,  there  is  continuous  
mutation  of  the  genes  which  code  for  betalactamase  enzymes.  Thus  
newer  betalactamases  having  broad   spectrum  of  activity  are  being  
developed.                                      
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                             One  such  carbapenemase  is  the  transferrable  
metallobetalactamase, a class B type of betalactamase  ( Ambler  
Classification ) which recognizes bivalent  metal  ions  mostly  zinc  for  
their  catalytic  activity. These metallobetalactamase  has  the  ability  to  
hydrolyse  penicillins,  cephalosporins,  carbapenenems  and  are  resistant  
to  betalactam  inhibitors  and  metal  ion  chelators  like  EDTA ( Ethylene 
Diamine Tetra acetic acid ), Mercapto acetic acid ( MAA ) and Thiol like 
compounds3.  But  it  lacks  the ability to hydrolyse aztreonam ( 
monobactum ). Metallobetalactamase  producing  isolates  are  now  
becoming  frequently resistant to aminoglycoside and fluoroquinolones,  but 
they are  still  susceptible  to  Polymyxin.   
                            The  genes  coding  for  the  production  of  
Metallobetalactamases  is  actually  a  part  of  an  integron  structure4.  
These   genes  can  either  be  a  part  of  the  chromosome  or  can   be  
carried  on  tranferable  plasmids.  Resistance  to  the  different  groups  of  
antimicrobial  agents  by  P.  aeruginosa  isolates  producing  
Metallobetalactamase  has  a  potential  for  rapid dissemination  to  various  
types  of  bacteria  because  it  is   plasmid mediated.                
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                           In 1991, Pseudomonas aeruginosa producing 
Metallobetalactamase  was  being  reported  for  the  first  time  from  Japan,  
and now  it  has  spread  to  almost  all  parts  of  the  world.   Nearly  5% -  
15%  of  the  hospital  acquired  infections  in  the  world  are  being  caused  
by Pseudomonas aeruginosa6.  In  India  Metallobetalactamase  producing  
Pseudomonas  aeruginosa  are  being  reported  from  7%  -  65%  in  
Ahmedabad7.  Because  of  the  emergence  of  antibiotic  resistance  in P. 
aeruginosa,  there  has  been  increased  rate  of  secondary  bacteremia,  
greater  duration  of  hospitalization  and  costs  and  higher  mortality  rates. 
                       For  this  scenario,  widespread  surveillance  is  required  
such  as  Implementation  of  simple  reliable  phenotypic  method  to  detect  
carbapenemase  and  metalobetallactamase  production  where  carbapenems  
and  other  betalactam  inhibitors  are  used  as  therapeutic  regimen.  This  
will  prevent  their  dissemination  thereby  initiating  effective  infection  
control  measures.  
                                     As  there  is  no  single  phenotypic  method  to  
detect  metallobetalactamase  enzymes in  clinical  isolates of 
nonfermenters  even  by  CLSI  guidelines,  the  most   reliable  
phenotypic  methods  must  be  standardized.  It  could  be  possible  to  
control  the  spread  of  resistance  as well  as  to  provide  optimum  
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treatment  to  patients.  Detection  of  gene  coding  for  carbapenem  
resistance  by  PCR  is  reliable  but  it  is  of  limited  practical  value  for  
daily  application  in  clinical  laboratories8.  Hence  the  present  study  
was  conducted  with  an  aim  to  evaluate  Pseudomonas  aeruginosa  
resistance  pattern  to  a  variety  of  antipseudomonal  antibiotics  and  to  
detect  metalobetalactamase  production  in  them  using  phenotypic  
methods  such  as 1)  MBL  E  Test,  2)  Combined  disc    test (CDT),  3)  
Double  disc  synergy  test (DDST )  and  4) The   Modified  Hodge  Test.  
These  phenotypic  methods  are  mostly  based  on  the  ability   of  
EDTA  like  metal  chelators  to  inhibit  the  activity  of  
metallobetalactamases. 
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                                  AIMS  AND  OBJECTIVES 
 
AIM: 
            To  isolate  Pseudomonas  aeruginosa  from  various  clinical  
samples  and  to  determine  its  antibiotic  resistance  to  various  
antipseudomonal  drugs. The  isolates  which  are  resistant  to  meropenem  
are  tested  for  various  phenotypic  methods  for  the  detection  of  
metallobetalactamase.                        
             
OBJECTIVES: 
1) To  isolate  Pseudomonas  aeruginosa  from  the  clinical  samples  
and  to  know   the  infections  associated  with  it. 
2) To  determine  their  sensitivity  pattern  to  various  antipseudomonal   
antibiotics. 
3)  To  correlate  the  meropenem  resistance  by  disc  diffusion  method  
and  its  MIC  by  E  Test  method. 
4) To  find  the  prevalence  of  Carbapenem  resistance  and  
metallobetalactamase  among  the  isolates. 
5) To  demonstrate  the  best  and  the  reliable  phenotypic  method  of 
metallobetalactamase  production  among  the  four  tests. 
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                                    REVIEW  OF  LITERATURE: 
PSEUDOMONAS AERUGINOSA:  
HISTORY:  
   1850:  Sedillot  observed  blue  green  discharges  on  surgical  dressings 
associated  with  infections . 
   1862:   Luke  observed  rod  shaped  microorganism  within  the  blue  
green  pus.   
   1882:   Carle  Gessard  first  isolated  the  organism  and  designated  them  
as  Bacillus  pyocyaneus. 
     1925:  Osler  discovered the  organism  mostly  causes  secondary  or  
opportunistic  infection  of  damaged  tissues  as  opposed  to  primary  
infection  in healthy  tissues9. 
     1960s:   Pseudomonas  aeruginosa  emerged  as  a  major  human  
pathogen  as  it  has  the  ability  to  cause  infections  in  burns  and  in  
immunocompromised  patients. 
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               In  Greek  Pseudo  means  
9,  aeruginosa   means  verdigris  that  is  bluish  green  in  colour. The  literal  
translation  of  blue  pus  is  Pyocyanaea10.  
                Due  to  the  fact  that  Pseudomonas  is  a  common  occurrence  in  soil,  
water,  plants  and  animals  it  is  observed  earlier  in  the  history  of  
microbiology.  Pseudomonas  is   frequently  present in  skin  and  normal  
intestinal  flora  of  normal  man  in  whom  it  is  a  saprophyte.  Pseudomonas  is  
found  everywhere  around  us:  hospitals,   nursing  homes,  medical  equipments,  
sinks  and  showers  in  hospitals etc. It  flourishes  as  a  saprophyte  in  human  
environment  in  warm  moist  conditions   such  as  drains,  hot  tubs,  whirlpools, 
flower  vases,  ponds,  washing   machines,  contact  lens  solutions,  respirators,  
humidifiers,  disinfectant  solutions,even  in  distilled water11. 
MORPHOLOGY: 
          Pseudomonas  aeruginosa  is  a  straight  or  slightly  curved  Gram  negative    
bacilli  with  a  length  of  1.5  to 3.0  µm  and  a  breadth  of   0.5  to  0.8  µm  by  
.  It  is motile  by  a single  flagellum  inserted  at  the  tip  of  the  cell . Fimbriae  
when  present  are  usually  polar  and  non  haemagglutinating .  It  is  strictly  
aerobic. It   is  non  acid  fast, do  not  form  spores  and  is  non  capsulated.     
                        Many  of  the  strains  which  are  isolated  from  respiratory  tract  
infections  in  patients  with  cystic  fibrosis  produce  strikingly  mucoid  colonies.  
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This  may  be  due  to  large  amounts  of  alginate  produced, which  is  an  
exopolysaccharide   consisting  of  mannuronic  and  guluronic  acids. When  such  
strains  are  examined  by  India  ink  technique,  the  exopolysaccharide  may  
appear  as  a  loosely  bound  extracellular  matrix  or  rarely  a  distinct  capsule. It  
is  to  be  noted  that  this  alginate  is  distinct  from  Pseudomonas  slime  which  
is  a  heterogenous  mixture  of  hexoses.  It  is  produced  on  prolonged  
incubation  in  the  media  with  low  nitrogen  ,high   carbon  content  by  all   
strains   of  the  species.  In  Pseudomonas  aeruginosa,  filamentation  cannot  be  
induced  under  oxygen  limitation  and  certain  growth  condition  like  other  
species  of  Pseudomonas12. 
CLASSIFICATION: 
                   Classification  and  typing  of  Pseudomonas  aeruginosa  is  being  
essential  for  epidemiological  purpose  because  of  its  importance  in  causing  
hospital  acquired  infection.  Palleroni  classified  Pseudomonas  into  five  rRna  
homology  groups which  is  based  on  ribosomal  RNA  DNA  homology  
studies.  Based  on  this  Pseudomonas  aeruginosa  is  classified  under  rRNA  
Group  112.   
                Gilardi  classified  Pseudomonas  into seven  major  groups  which  is  
based  on  phenotypic  characteristics.  Based  on  this  Pseudomonas  aeruginosa  
is  classified  under  fluorescent  group.  It  produces  a water soluble  pyoverdin  
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pigment  which  fluoresces  white  to  blue  green  under  400nm  (long  
wavelength)  ultraviolet  light  and  it  does  not  accumulate poly - -
hydroxybutyrate.. Fluorescent  pigment  production  is enhanced  in  media  
containing  high  phosphate  concentration13. In  earlier  days, classification  by  
serotyping,  bacteriophage  typing  and bacteriocin  (Pyocin, aeruginosin)  typing  
were  used  but  it  is  not  used  now  due  to  lack  of  discriminatory  power.    
 CULTURAL CHARACTERISTICS: 
                Pseudomonas  aeruginosa,  an  obligate  aerobe  can  readily  grow  on  
many  types  of  culture  media  producing  musty,  mawkish,  earthy,  sweet  
grape  like  odour. (Older  cultures  produce  corn  tortilla  like  odour).  This  
odour  is  caused  by  the  presence  of  aminoacetophenone.   
                  On  nutrient  agar,  iridescent  patches  which  is  nothing  but  a  moth  
eaten  type  of  colonial  lysis  with  a  metallic  sheen  are  seen  with  crystals  
beneath  the  patches.  Though  iridescence  resembles  lysis  by  bacteriophage  
actually there  is  no  association  with  phage  activity.  Frequently  we  can  
observe  the  colony  dissociation  from  one  type  of  colony  to another  in  
primary  diagnostic  plates  and  in  subcultures  but  it  is  not  necessary   that  it  
belongs  to  more  than  one  strain  of  species. 
                                                 Blood  agar  plate  shows  the  characteristic  
appearance  that  is  large,  mucoid,  rough  gray  colonies  with  a  spreading  
 11 
 
periphery  sometim
oxidase  production.  On  MacConkey  Agar, Pseudomonas  aeruginosa   appears  
as  pale  non  lactose  fermenting  colonies, lie  flat  frequently  producing  a  
gelatinous  or  slimy  appearance, mainly  in  areas  of  heavy  growth  associated  
with  pigmentation  and  have  serrated  edges.  In  Nutrient  broth  it  forms  
surface  pellicle  and  makes  the  medium  turbid.  
                             There  are  six  different  colonial  types  when  grown  on  
nutrient  agar  at   37  º C  after  aerobic  incubation  for  24  hours.  
COLONY  
TYPE 
                           COLONY DESCRIPTION 
TYPE 1 Large,low convex, oval with long axis in the inoculum streak 
line, rough in appearance, sometimes it is surrounded by a thin 
serrated skirt like growth. Most common and easily recognized. 
TYPE 2 Small,domed,smooth in appearance,also described as coliform-
like.Mostly isolated from environmental sources. 
TYPE 3 Small  and  appear  rough. 
TYPE 4 Small  and  appear  rugose. 
TYPE 5 Mucoid, alginate producing,sometimes merges colonial growth. 
On further incubation, copious exopolysaccharide  can  dip on 
the  inverted petridish lid. Mostly isolated in patients with cystic 
fibrosis. 
TYPE 6 Dwarf  type  colony,  sometimes  appear  mucoid. 
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             Small  colony  variants  will  lack  motility, require   prolonged  incubation  
time,are  hyperpiliated,  adhere  to  agar  surfaces,  and  in  liquid  media  show  
autoaggregative  properties. The  mucoid  phenotype   is  also  seen  in  occasional  
isolates  from  patients  with  AIDS.   
                There  are  multiple  selective  media  containing inhibitors  like  
acetamide,  nitrofurantoin,  phenenthroline, and  cetrimide14 .Selective  media  like  
cetrimide  agar  can  be  used  to  isolate  this  organism  from  mixed  flora  like in  
feces or  other  specimens. Cetrimide   acts  as  a  detergent  and  inhibits  most  of  
the  bacteria;  this  medium  also  enhances  the  production  of pyoverdin  and  
pyocyanin  pigment.  P.aeruginosa  can  grow  well  at  37 - 42 º C;  but  its  
growth  at  42 º C  differentiates  it  from  other  Pseudomonas  species belonging  
to  the  fluorescent  group15. Optimum  pH  is  7.4  7.6.  It  can  also  be  grown  
anaerobically  in  the  presence  of  nitrate  which  acts  as  a  terminal   electron  
acceptor. 
PRODUCTION   AND  IDENTIFICATION  OF  PIGMENTS: 
PYOCYANIN  AND FLUORESCEIN: 
                       Pseudomonas  aeruginosa  alone  produces  pyocyanin,  the  
distinctive  blue   pigment   which  is  formed  best  in  peptone  media.  It  is  
water  and  chloroform  soluble  phenazine  pigment  which  is  non  fluorescent. 
In  the  liquid  cultures  of  P.aeruginosa  which  is  grown  without  agitation  
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often  we   can  observe  a  pyocyanin  containing  layer  in  the  upper  part  of  the  
broth   at  the  intersurface  of  air / liquid.  In  conditions  where  pyocyanin  
presence  is  obscured  by  other  pigments  or  it  is produced  in  small   quantity,  
it  is  observed  more  readily  by  shaking  a  broth  culture  or  an  agar  slope  
culture  with  a  few  milliliters  of  chloroform .  On  standing  in   the  chloroform  
pyocyanin  will  appear ( but  not  fluorescein )  once  the  phases  have  separated  
out . Pyocyanin  has  the  capacity  to  emerge  P.aeruginosa  as  the  dominant  
bacterium  in  mixed  infections  because  it  can  inhibit  the  growth  of  many  
other  bacteria. 
                Some  strains  produce  pyoverdin ( fluorescein ),  a  green  coloured  
pigment,  soluble  in  water  but  not  in  chloroform. Fluorescein  is  best  
observed  in  a  suitable  dark  chamber  when  the  cultures  are  illuminated  with  
UV  light. Most  of  the  pigment   enhancing  media  is  ba
A  and  B  for  production  of  pyocyanin  and  fluorescein  pigments  respectively.  
            As  most  of  the  strains  of   P.aeruginosa  has  the  capacity  to  produce  
both  pigments,  the  media  was   developed  so  that  one  pigment  production  is  
enhanced  while  suppressing  the  other  pigment  production.  Pyocyanin  
production  is  enhanced  by  Pseudomonas  isolation  agar   in  normal  practice  
which  combines  the  selective  agent  irgasan  with  pyocyanin  enhancing  
properties  of  medium  P ( bacto  peptone  and  agar,  magnesium  chloride,  
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potassium  sulphate,  distilled  water) . Iron  limitation  conditions  can  enhance  
the  pigment  production  because  the  pigments  act  as  siderophores in  iron   
uptake  systems   of  the  bacteria. Generally,  non-dye  containing  media  
enhances  the  pigment  visualisation. 
PYORUBIN  AND  PYOMELANIN: 
          Pyorubin,  the  dark  red  coloured  pigment  and  pyomelanin,  a  black  
coloured  pigment  are  the  other  pigments  produced  by  P.aeruginosa.  While 
identifying  these  pigments  caution  should  be  exercised  because  prolonged  
exposure  of  pyocyanin  to  air  can   produce  a  brownish  oxidation  products  
and  acidification  of  pyocyanin may  produce  a  red  colour.  Pyorubin  but  not  
pyomelanin  is  produced  when  grown  in  1%  DL  glutamate.  Similarly  
minimal salts  medium  which  is  supplemented  with  1 %  tyrosine.Alternatively  
pyomelanin  production  is  also  detected  by  using  Furunculosis  Agar.  Pigment 
production  can  be  enhanced  by  growing  organism  in  gelatin -,  potato -,  or 
milk - containing media  and  by  incubating  them  at  25  to 30 º C. 
BIOCHEMICAL  CHARACTERISTICS: 
                Pseudomonas  aeruginosa  is  oxidase  positive,  catalase  positive  and 
motile. The  metabolism  is  non  fermentive  and  oxidative. There  is  no  Indole  
and  Hydrogen  sulfide  production.  Citrate  utilization  test  is  positive.  There  is   
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no  hydrolysis  of  urea.  Methyl  red  reaction  as  well  as  Voges  Proskauer  
reactions  are  negative.  There  is  oxidative  utilization  of  glucose  forming  only  
acid.  Since  this  weak  acid  produced  by  P.aeruginosa  cannot  be  detected  by  
used  to detect  the  oxidative  attack  on  sugars16.  Xylose  and  fructose  is  also  
utilized  oxidatively.  In  nitrate  reduction  test nitrates  are  reduced  to  nitrites  
and  to  gaseous  nitrogen  further. In  LAO  Test, L Arginine  dehydrolase  test  is  
positive.  L Lysine  decarboxylase  and  L Ornithine  decarboxylase test  is  
negative. Gelatin  liquefaction  is  produced16 .  On  triple  sugar  iron  agar,  the  
reaction  is  alkaline  over  no  change  in  growth. 
ANTIGENIC  CHARACTERISTICS: 
There  are  17  distinct  group  specific  O  antigens  which  are  heat-stable  and  at  
least   2  H  antigens  which  are  heat-labile.Based  on  standard  slide  
agglutination  procedures,  these  antigens  are  recognised.  For  epidemiological  
typing  technique   only  the  serological  characterization  is  primarily  used.  It  is  
not  used  for  diagnostic  confirmation  of  species  identity. 
SENSITIVITY  TO PHYSICAL  AND  CHEMICAL  AGENTS: 
             Pseudomonas  aeruginosa  can  be  killed  at  55  º C  in  one  hour. It  can  
survive well   in  wet  environments  and  not  very  resistant  to  drying.  It  
exhibits  a  very  high  degree  of  resistance  to  chemical  agents.  It  is  resistant  
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to  the  following  common  antiseptics  and  disinfectants  Quarternary  
ammonium compounds, hexachlorophane,  chloroxylenol.   It  can  also  grow  in  
bottles   of  such  antiseptic  lotions  which  are  kept  for  use  in  hospitals.  It   
can  pump  the  antiseptics  actively  out  of  the  cell17.  P.aeruginosa  can  also  
grow  in  cetrimide  or  dettol  selective  media.  It  is  sensitive  to  the  following  
chemicals  such  as  acids,  silver  salts,  beta  glutaraldehyde  and  strong  phenolic  
disinfectants.  Silver  sulphonamide  compounds  are  used  topically  in  burns  
because  of  its  susceptibility  to  silver. 
PATHOGENICITY  AND VIRULENCE  FACTORS OF PSEUDOMONAS  
AERUGINOSA: 
      Pseudomonas  aeruginosa  infection   occurs  by   exposure  to  contaminated  
medical  devices  and  solutions;  introduction  by  penetrating  wounds;  ingestion  
of  contaminated  food  or  water;  person  to  person  transmission  is  assumed  to  
occur18. Consuming  salad  vegetables  which   is  contaminated  with  
pseudomonas  possess  a very  high  risk  for  immunocompromised  patients  
admitted  in  intensive  care  units. It  produces  many  substances  which  enhance  
the colonization  and  infection  of  the  host  tissue. 
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Virulence Factor Biologic  Activity 
Alginate It  is  a  capsular  polysaccharide  allowing  the    
bacteria  to  attach  to  epithelial  cell  surfaces  of  
lung. Can  form  biofilms  thus  protecting  the  
bacteria  from  antibiotics  as  well  as  immune  
system. 
Neuraminidase From  GM1 ganglioside  receptors  it  removes  the  
sialic  acid  residues  thus  facilitates  the  binding  of  
pili. 
Pili Surface appendages adhere the organism to GM1 
ganglioside  receptors  on  host  epithelial  cell  
surfaces. 
Lipopolysaccharide Produces  endotoxin  causing  sepsis  syndrome. 
Enterotoxin Interrupts  normal  gastrointestinal activity  leading  
to  diarrhea. 
Exotoxin A Interrupts  cell activity  and  macrophage  response,  
causes  tissue  destruction,inhibits protein  synthesis. 
Elastase Disrupts neutrophil activity, cleaves complement  
components  and  immunoglobulins. 
Leukocidin Inhibit   lymphocyte   and   neutrophil   function. 
Phospholipase C Destroys  pulmonary  surfactant,  cytoplasmic  
 membrane.Inactivates  opsonins. 
Pyocyanins Disrupt  respiratory  ciliary  activity,  cause 
oxidative  damage to tissues  especially  lung, 
suppress  other  bacteria. 
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An  unusual  mucoid  morphotype  of  Pseudomonas aeruginosa  is  
recovered  from  respiratory  secretions  of patients  with  cystic  fibrosis.  
The mucoid  morphotype  is  due  to  the production  of  alginate,  a  
polysaccharide   which  surrounds  the  cell. Alginate is  responsible  for  the  
poor  prognosis  and  high  mortality  rates  among cystic  fibrosis  patients13. 
EPIDEMIOLOGY: 
                            Pseudomonas  aeruginosa  has  low  intrinsic  virulence  but  
approximately  it  accounts  for  10 %  of  hospital  acquired  infections11. Usually  
in  open  community  the  carriage  rate  is  10-15 %   but  in  hospital  acquired  
the  carriage  rate  is  30 %  and  the  patients  will  start  to  excrete  the  organism  
in  a  very  short  period  after  admission.  Healthy  carriers  will  harbour   the  
strains  in  the  gastrointestinal  tract . 
TYPING  SYSTEMS: 
          There  are  two  different  typing   methods  ; 
1)  Phenotyping  methods: 
      The  phenotyping  methods  are  LPS  serotyping  and  phage  typing.  But  
now,  the  Genotyping  methods    have  supplanted   conventional  schemes  
which  are  based  on  phenotypic  characteristics. 
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2)  Genotyping  methods . 
           The  Genotyping  methods  are  used  for  epidemiological   purposes  even  
for  typing isolates  from  cystic  fibrosis  patients.  But  the  limitation  of  this  
method  is   that  it  may  not  be  available  in  all  clinical  diagnostic  
laboratories.  The   four  different  genotyping  methods  are : 
A) RFLP:    
         Restriction  Fragment  Length  Polymorphism   depends  upon   the  genetic  
diversity  which  exists  upstream  of  the  gene  for  exotoxin  A  (exo A)  in  P.  
aeruginosa.  This  method  of  typing  has  proved  superior  to  all  other  
phenotypic  method  for  typing  P.  aeruginosa.  Individual  cystic  fibrosis  
patients  are  mostly  infected  with  same   strain  even  when  there  are  changes  
in  pilin  protein  expression  that  are  demonstrated  by  Pilin  gene  RFLP.  
Disadvantages:  1)  Cumbersome  nature.  2)  Relatively  weak  discriminatory  
power  when  compared  to  newer  methods.          3)   Predominant  use  of  two  
radioactive  probes.                                                                            
B)  PFGE: 
                           Since  P.  aeruginosa  has  substantial  genetic plasticity,  more  
than  three  band   difference  can  be  seen  among  isolates  typed  by  Pulsed  
field  gel  Electrophoresis ( PFGE )  and  they  are  considered  to  be  of  same  
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that  three  or  fewer  band  difference  between  two  isolates  should  be  
considered  from  the  same  strain  because  such  differences  are  due  to  only  
one  genetic  event.  Advantages:  1) High  discriminatory  power, 2) Universal  
utility  for  typing   any  bacterial  specimen.  Disadvantages:  Inability  to  
evaluate  a  large  number  of  isolates  rapidly  as  it  requires  specialized  
equipments. 
C)  PCR  Based  Typing  Methods: 
      They   are  directed  against  random  but  relatively  frequent  encoded  
sequences  or  at  known  elements  within  the  genome.  The  latter  method  
RAPD,  Random  Amplified  Polymorphic  DNA analysis  used  for  typing  P. 
aeruginosa  has  been  proved  quite  robust.  It  must  be  consistently  run  to  
yield  reproducible  results  on  same  equipment.  Data  from  RAPD Analysis  are  
highly  consistent  with the  data  from  PFGE.   To   produce   more  
discriminatory  data,  PCR  amplification  products  are  digested  with  restriction   
enzymes.  
D)  Multilocus  Sequence  Typing: 
                       It   has  been  recently  only  employed  for  typing  P. aeruginosa. In  
this  method  first  the  special   genes  are  amplified  by  PCR  and  then  the  
gene  products  are  sequenced.  It  is  done  only  in  very  specialized  centres  but  
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it  can  prove  relatedness  among  isolates  by  providing  highly  reliable  data.   
Advantage:  Highly   discriminative  among  gene  typing  tool.  Disadvantage:  1)  
Extremely   time  consuming  2)  Very  expensive14.  
BIOFILMS:  
                        Biofilms  of  P. aeruginosa  has  the  ability  to   cause  
chronic  opportunistic  infections  mainly  in  the  elderly  and  the  
immunocompromised  patients  which  pose  a  serious  problem  for  
industrialized  societies  in  providing  medical  care.  The  most  important  
property  of  biofilms  is  that  they  show  marked  resistance  to  chemical  
and  physical  agents19. With  traditional  antibiotic  therapy  alone  they  
cannot  be  treated  effectively. Biofilms  assume  to  have  protecting  
function   from  adverse  environmental  factors  for  these  bacteria.  P. 
aeruginosa  is  being  considered  a  model  organism  for  its  use  in  the  
study  of  antibiotic  resistant  bacteria  as  it  causes  nosocomial  infections.  
It  is  from  the  treatment - resistant  bacteria  like  P. aeruginosa,  
researchers  try  to  learn  more  about  the  switch  from  planktonic  growth  
to  the  biofilm  type of  growth  and  the  molecular  mechanisms  involved  
in  it.   They  also  acquire  knowledge  about  the  quorum  sensing  
mechanism  from  these  bacteria.  This  should definitely  contribute  to  the  
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development  of  new  drugs  and  better  management  of  chronically  
infected  patients  clinically.  
INFECTIONS  CAUSED  BY  PSEUDOMONAS  AERUGINOSA: 
              Pseudomonas  aeruginosa  infections is  more  prevalent  among  patients 
with burns,  acute  leukemia,  organ  transplants,  cystic  fibrosis,  intravenous  
drug  addiction. Urinary  tract  infections, lower  respiratory  tract  infections  can  
be  severe  and  more  life  threatening  in  immunocompromised  hosts.  Infections  
more  commonly  occur  at  sites  such  as  indwelling  catheters,  tracheostomies,  
the external  ear,  burns  and  weeping  cutaneous  wounds  where  there  is  a  
tendency  for  the  moisture  to   accumulate.  Patients  with  burns  acquire  the  
infection  by  contact  spread  , directly  by  the  hands  of   medical  staff  or  
indirectly  by  contaminated  apparatus. In   most  of  the  Pseudomonas  
aeruginosa  infections  symptoms  and  signs are  related  to the  organs  involved  
and  are  non  specific.  Thus  the  infections  caused  by  P.  aeruginosa  are  
described  below  in  the  following  order. 
1)   Bacteremia. 
2)   Bone  and  joint  infection. 
3)   Central  Nervous  system  infections. 
4)   Ear  infections. 
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5)   Endocarditis. 
6)   Eye  Infections. 
7)   Gastrointestinal  Infections. 
8)   Respiratory  Infections. 
9)   Skin  and  soft  tissue  infections. 
10)  Urinart  Tract  Infections. 
11)  Acquired  Immuno  Deficiency  Syndrome  Related  Infections 20.  
Bacteremia:                                 
                  P. aeruginosa  is  one  of  the  cause  of   hospital  acquired  bacteremia  
in   the  intensive  care  units. P. aeruginosa  causes  6%  of  all  bacteremias  and  
75%  of  nosocomial  bacteremias. The  poor  prognostic  factors  associated  with  
P.aeruginosa  bacteremia  are  granulocytopenia,  septic  shock,  inappropriate  
antimicrobial  therapy,  and  the  presence  of  septic metastatic  lesions.   The  
mortality  of   P. aeruginosa  bacteremia  ranges  from  15% - 55 %  and  it  
depends  on  the  underlying  disease,  the  source  of  infection   and  presence  or  
absence   of  septic  shock.   In  infants  and  debilitating   patients,  Pseudomonas  
aeruginosa   can  invade  the  vascular  walls  of  the  blood  vessels  and  thus  has  
a propensity  to  spread  in  the  body. 
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               There  are  two  types  of  Pseudomonas  bacteremia -  Primary  and  
Secondary. 
Primary  bacteremia  is  more  common  among  patients  with  hematologic  
malignant  neoplasms  suffering  from  neutropenia  induced  by  chemotherapy  
and in  those  undergoing  invasive  procedures.  Secondary  bacteremia  is  more   
commonly  associated  with  the  following  infections   gastrointestinal,  
respiratory,  indwelling  intravenous  catheter  associated  and  skin  and  soft  
tissue  infections. 
            The  clinical  signs  and  symptoms  invariably  similar  to  gram  negative  
becteremia   by  other  organisms.  The  few  pathognomonic  signs  indicating  
Pseudomonas  bacteremia  are  respiratory  failure,  ecthyma  gangrenosum  skin  
lesion and  jaundice.  These  skin  lesions  are  also  associated  with  bacteremia -  
cellulitis  with  sharply  demarcated  areas  which  become  hemorrhagic   as   well  
as  necrotic,  vesicles  that  are  small  and  painful,  maculopapular  eruptions  on  
the  trunk   and   metastatic   abscess  on  extremities. 
Bone  and  Joint  Infections : 
                   P. aeruginosa  cause  infections  of   the  bone  and  joints  by  either  
direct   inoculation  or  by  contiguous  spread  or  by  hematogenous  
dissemination  from  distant  sites.  The  predisposing  factors  for  these  
infections  are  diabetes  mellitus, intravenous  drug  abuse,  chronic  debilitation  
and  penetrating  injury.  Pseudomonas  has  more affinity  to  involve  
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fibrocartilginous  joints  of  axial  skeleton,  cartilage,  joint  space,  synovium  and  
cartilaginous  bone.  
                      Sternoarticular  pyoarthrosis  caused  by  Pseudomonas  occurs  
mainly  in  intravenous  drug  users.  The  erythrocyte  sedimentation  rate  is  high  
always  and  there  is  an  accompanying  leukocytosis.  Synovial  fluid  aspiration  
will  reveal  the  characteristics  of  the  pyogenic  infection.  Though   it  is  
difficult  to  identify  from  gram  stain  of  synovial  fluid  alone,  P.  aeruginosa  
can  be  easily  isolated  by culture. 
              Vertebral  osteomyelitis  by  P. aeruginosa  occurs  in  elderly  people  
associated  either  with  complicated  urinary  tract  infections or  genitourinary  
instrumentation  or    during  surgery.  Lumbar spine  is  most  commonly  
involved. Whereas  cervical  spine  is  most  commonly  involved  in  intravenous  
drug  users.  P.  aeruginosa  is  identified  as  the  cause  of  vertebral  
osteomyelitis  by  cultural  characteristics  or  by  even  histologic  examination  of  
specimens  which   are  obtained  by  aspiration  under  fluoroscopic  guidance  or  
by  needle  biopsy. 
      During  pelvic  surgery  or  in  intravenous  drug  users,  P.  aeruginosa  causes  
infection  of  the  pubic  symphisis.  There  is  increased  erythrocyte  
sedimentation  rate  and  leukocytosis  is  rare.  Since  it  is  difficult  to  
distinguish  osteomyelitis  from  osteitis  pubis  which  is  a  non  infectious  
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disease,  needle  aspiration  or  biopsy  of  pubic  symphysis  is  necessary  to  
prove  infectious  etiology. 
                   P. aeruginosa  being  the  most  common  cause  of  osteochondritis  of  
the  dorsum  of  the  foot,  after  puncture  wounds  of  foot  by  sharp  objects  like  
nail.  The  infection  mostly  occur  in  children  and  occasionally  in  adults.  
Because  P.aeruginosa  has  the  propensity  to  survive  in  the  moist  
environment  that  occurs  in  the  soles  of  running  shoes  which  are  old. Thus  
it  proves  the  predilection  of  fibrocartilginous  joints   which  are  what  exactly  
found  in  small joints  of  the  foot.  Aspiration  of  the  infected  joint  may  be  
sent  for  culture.        
                 Chronic  contiguous  osteomyelitis  arises  by  direct  inoculation  or by  
direct  extension  from  the  infected  soft  tissue  overlaying  the  bone  and  least  
likely  by  hematogenous  spread.  This  is  implicated  in  the  type  of  infection  
following  a  penetrating   trauma,  compound  fracture  or  surgery  involving  the  
bone.  These  infections  can  also  complicate  peripheral  vascular  disease  with   
pressure  necrosis  of  soft  tissue  and  skin  or  peripheral  neuropathy  or  
decubitus  ulcers  overlaying  the  bone.  Unlike   Staphylococcus  aureus,  
Pseudomonas   osteomyelitis  is  less  destructive  and  more  indolent.   
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Central  Nervous  System  Infections:                        
                  Pseudomonas  aeruginosa  causes  central  nervous  system  
infections  (brain  abscess  or  meningitis)  either  by  
i)    direct  inoculation  of  the  brain  or  sub  arachnoid  space  secondary  to  
surgery  or  penetrating  head  trauma, 
ii)   extension  from  infected  mastoid  or  paranasal  sinuses  or  from  other 
contiguous  focus. 
iii)    blood  stream  infections. 
             The  other  predisposing  conditions  or  factors  are  spinal  anaesthesia,  
previous  lumbar  puncture, cerebrospinal  fluid  leak,   intraventicular  shunt  or  
reservoir and  cancer  of  head  and  neck  or  subarachnoid   space.  It  can  cause  
brain abscess,  meningitis  when  introduced  by  lumbar  puncture. The  clinical  
course  can  be  from  several  hours  to  days  and  can  be  accompanied  by  
septic  shock.  Occasionally  Pseudomonas  meningitis  may  develop  insidiously, 
when  it  is  associated  especially  with  a  contiguous  site  of  infection  or  
subarachnoid  space   cancer.      
Ear  infections: 
      
meatus  caused  by  Pseudomonas.  It  is  a  self limiting superficial  infection  
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which  usually      resolves  spontaneously  or  responds  to  local  treatment. It  can  
also occur  in  deep  sea  divers ( under  hyperbaric  conditions )  which  is  a  
community acquired  infection. 
                               P. aeruginosa  causes  invasive  ( malignant )  otitis  externa  in  
elderly  diabetic  patients  and  occasionally  in  young  infants  with  serious  
underlying  diseases.  The  pathogenesis  behind  this  invasive  necrotizing  
pocess  is  explained  by  the  penetration  of  the  epithelium  in  the  floor  of  the  
lateral  part  of  external  auditory  canal  at  the  junction  between  cartilage  and  
bone  and  invasion  of  underlying  cartilage,  soft  tissue  and  bone.  The  risk  
factors  are  aural  water  exposure  and  antecedent  ear  irrigation.   
                       After  bypassing  the  tympanic  membrane  and  middle  ear,  the  
infection  enters  the  parotid  space  or  retromandibuar  area   and  then  to   
mastoid  air  space  and  temporal  bone  and  to  the  base  of  the  skull.  There i) 
at  stylomastoid  foramen, it  involves  the  seventh  cranial  nerve,  ii)  at  jugular  
foramen ,  it  involves  the  ninth, tenth, eleventh  cranial  nerves,  iii)  at  
hypoglossal  canal,  it  involves  the  twelfth  cranial  nerve.  There  is  chance  that  
lateral  and  sigmoid  sinuses  to  be   involved  and  further  to  the  vascular  
channels  at  the  base  of  the  skull.  The  infrequent  complications  are  
meningitis  and  brain  abscess.  There  is  almost  always  a  marked  increase  in  
ESR  sedimentation  rates.  
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                              Most  often  P.  aeruginosa  causes  Chronic  Suppurative  Otitis  
Media (CSOM )  and  at  times  even  in  combination  with  other   organisms. 
Endocarditis: 
                               Pseudomonas  aeruginosa  causes  native  heart  valve  
infection  in  intravenous  drug  abusers  and  also  causes  prosthetic  heart  valve  
infections.  The  tricuspid  valve  is  more  frequently  affected  in  drug  addicts  
and  then  the  other  three  valves  along  with  mural  endocardium  of  both  
atrium  can  also  be  affected.  Right  sided  disease  is  subacute  but  the  left  
sided  disease  is  more  acute.  Diagnosis  is  based  on  positive  blood  cultures  
and  appropriate  clinical  signs.  Abnormal  transesophageal  or  transthoracic  
findings  are  confirmatory  of  endocarditis.   
Eye  Infections: 
                Pseudomonas  aeruginosa  causes  endophthalmitis  and  keratitis ( 
corneal  ulcer ).  When  it   is  introduced  by  direct  inoculation  or  
hematogenous  spread  into  the  eye  which  is  avascular  having  an  
immunologically  sequestered  environment,  it  can  cause  destructive,   
devastating  and  sometimes  sight  threatening  disease.  As  the  treatment   is  
also  complicated  by  the  blood  eye  barrier  which  limits   the  antibiotic  
delivery  to  infected  intraocular  structures. 
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                      Eye  trauma  though  extremely  minor  can  predispose  to  corneal  
infection  by  P.  aeruginosa  by  causing  a  break  in  the  epithelial  surfaces  
allowing  easy  access  of  bacteria  to  the  underlying  corneal  stroma  .The  
predisposing  conditions  of  Pseudomonas  keratitis  are  warm,  humid  
environments,  contact  lens  especially  soft  extended  wear  type  users,  having  
underlying  ocular  conditions,  patients  treated  with  topical  steroids  or  
contaminated  eye  medications,  coma,  tracheostomy  or  endotracheal  
intubation,  extensive  burns,  intensive  care  and  ocular  irradiation. 
                       Pseudomonas  keratitis   usually  starts  as  a  small  central  ulcer  
which  can  spread  centrifugally  and  involves  the  entire  cornea  part  of  
surrounding  sclera.  When  it  penetrates  more  deeply  into  the  underlying  
stroma  involving  the  whole  of  cornea. it  can  cause  corneal  perforation within  
24 - 48  hours. Pseudomonas  corneal  ulcer  should  be  considered  as  a  medical  
emergency  because  perforation  into  the  anterior  chamber  will  lead  to  a  
rapidly  destructive  intraocular  infection  which  leads  to  blindness.  Scrapings  
from  the  floor  of  the  corneal  ulcer  are  examined  by  Gram stain  and  then  
cultured.  Antibiotic  susceptibility  testing  is  to  be  done  for  all  isolates  
because  of  the  increasing  antimicrobial  resistance  in  Pseudomonas  corneal    
infections.   
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                               Pseudomonas  endophthalmitis  occurs  as  a  complication  of  
penetrating  injuries,  intraocular  surgery,  perforating  corneal  ulcer  or  
bacteremia  originating  outside  the  eye.  It   is  an  acute  fulminant  disease  
which  rapidly  causes  losss  of  vision.  This  characteristic  of   Pseudomonas  
endophthalmitis    distinguishes  it  from  other  less  virulent  bacteria  like  
Staphlococcus  epidermidis  which  causes  less  severe    form  of  
endophthalmitis.  These  can  involve  vitreous  and  cause  panophthalmitis.  
Aspiration  material  from  anterior  chamber  and  vitreous  cavity    obtained  for  
Gram  stain  and  culture  are  essential  for  proper  management  of  
Pseudomonas  endophthalmitis .Pseudomonas  keratitis,  corneal  ulcer  infections  
and  endophthalmitis   should  be  approached  as  medical  emergency  because  it  
can  be fulminant  and cause  permanent  loss of  vision.     
Gastrointestinal  Infections: 
                           The  gastrointestinal  tract  is  the  site of  primary  infection  and  
also  the  common  port  of  entry  for  Pseudomonal  blood  stream  infections. In  
young  infants,  it  is  the  common  cause  of  necrotizing  enterocolitis.  Typhlitis,  
a  similar  disease  occurs   in neutropenic  cancer  patients  but  it  is  
polymicrobial  and   Pseudomonas  is  the most  important  among  other  
bacterias.  The  sites  involved  are  distal  ileum,cecum,ascending  colon-  
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proximal  part.  In  patients  with  acute  leukemia,  necrosis,,gangrene  occurs 
which   leads  to  perforation  and  peritonotis . 
                          Shangai  fever  is  the   historical   name  of  syndrome  which  
resembles  the  enteric  fever.  It  presents  with  constipation  or  diarrhea,  fever  
lasting  for  about  1 - 2  weeks  and  rash.  From  these  cases  Pseudomonas  is  
isolated  from  stool yet  its  causative  role  is  uncertain. 
                Sometimes  gastrointestinal  infection  epidemics  occur   in  newborns  
and  young  infants  in  maternity  and  paediatric  wards  due  to  contaminated  
milk  feeds.  
Respiratory  Infections:   
                                 P.aeruginosa  causes  acute,  bacteremic  or  non  bacteremic  
pneumonia  mainly  in  immunocompromised  patients.  It  also  causes  chronic  
respiratory  tract   infection  in  patients  with   bronchiectasis  and  cystic  fibrosis.     
In  patients  who  are  admitted  in  intensive  care  units,  there  is  upper  
respiratory  tract  colonization  by  P. aeruginosa  which   is  due  to  alteration  of  
the  buccal  epithelial  cells  due  to  loss  of  fibronectin  and  loss  of  cells  anti 
adhesive  properties.  Through  aspiration  of  upper  respiratory  tract  infections,  
patients  suffering  from  either  congestive  heart  failure, chronic  lung  disease,  
previous  antibiotic  therapy,  on  ventilatory  or  respiratory  inhalation  therapy  
are  predisposed  to  lower  respiratory  tract  infections.  Neutropenic  patients  or  
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adults  receiving  mechanical  ventilation  are  at  increased  risk  for  acquiring  
VAP  or  other  pneumonias  caused  by  P. aeruginosa16. Thus  it  is  the  leading  
cause  of  pneumonia  in  ICU  patients.  Even  community  acquired  pneumonia  
occur  in  normal  hosts  but  it  is  uncommonly  seen. 
                   In  non  bacteremic  pneumonia  microabscess   and  necrotizing  
alveolar  septa  occur  but  the  blood   vessels  are  not  involved.  But  in  
bacteremic  pneumonia  mainly  in  neutropenic  patients  invasion  of  blood  
vessels  occur  which  spread   to  metastatic   sites  of  infection.  In   both   the  
lung  fields  small,  nodular,  hemorrhagic  lesion  occur  diffusely  which  on   
microscopic  examination  involve   small  blood  vessels,  have  many  bacteria,  
and  lack    leukocyte  reaction.  Thus  they  represent  the  pulmonary  counterpart  
of  ecthyma  gangrenosum  which  involves  the  skin.  The  disease  course  is  
fulminant  mainly  in  neutropenic  patients  and  it  ends  fatally. 
           Between  3  18  years  of  age  most  patients  with  cystic  fibrosis   suffer  
from  chronic  lower  respiratory  tract  infections  caused  by  P.  aeruginosa   
mucoid  strain. In CF  Patients,  the  infecting   strain  may  switch  from   the  
environmental  phenotype     ( LPS  smooth, motile,  nonmucoid)  to  CF 
phenotype ( LPS  rough,  nonmoile,  mucoid)  during  the   course  of  infection. 
Leukocytosis  is  usually  present. These  infections  persists  for  life  if  they  are  
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once  established  and  will  follow  a  progressive  waxing  and  waning  course 
which  are   arrested  by  frequent  exacerbations.   
Skin  and  soft  tissue  Infections: 
a)  Ecthyma  gangrenosum:  This  focal  skin lesion  may  be  characterized  by  
surrounding  erythema,  hemorrhagic  necrosis  and  vascular  invasion  by  
bacteria.  It  is  sometimes  associated  with  P.  aeruginosa  septicemia which  is  
also  having  other  skin  lesions  like  cellulitis,deep  abscess,  subcutaneous  
nodules,  bullae,  vesicular  or  pustular   skin   lesions.  In  neutropenic  patients  
Pseudomonas  sepsis  is  complicated  by  large  destructive  lesions  of  the  skin  
or  mucous  membrane.  These  lesions  can  produce  gangrene  of  face,  
oropharynx,  extremities  or  perenium.   
b)  Pyoderma:  Primary  Pseudomonas  pyoderma  resembles  ecthyma  lesions  of  
Pseudomonas  bacteremia.  They  can  be  focal  or  diffuse.  Predisposing  factors  
arise  due  to  breakdown  of  skin  secondary  to   trauma,  severe  burns,  
neutropenia  occurring  secondary  to  cancer  chemotherapy. 
appearance  to  distinguish  it  from  other  bacteria.  But  it  produces  a  
characteristic  fruity  odour  and  blue  green  exudate  by  pyocyanin  pigment  
production  which  are  seen  more  commonly  on  wound  bandages  than  within   
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the  wound  itself.  Any  non operative  or  post  operative  wound  infection  can  
be  caused  by  P.  aeruginosa  and   it  should  be  seriously  considered  if  it  is  
contaminated  with  soil,  water,  plant  material.  Occasionally  nosocomial  
outbreak  of  Pseudomonas  infection  can  occur.   
d)  Dermatitis:  P.  aeruginosa  causes  self  limited,  pruritic,  diffuse,  
maculopaular  or  vesiculopustular  rash  associated  with  exposure  to  
contaminated  hot  tub,  spa,  whirlpool.  These  often  occur  as  a  common  
source  outbreak.  Rashes  are  more   pronounced in  bath  suit  covered  areas  but  
can  also  be  diffuse  and  rarely  systemic  symptoms  occur.   Usually  these  
rashes  require  no  specific  therapy  except  in immunocompromised  patients  
like  patient  with  AIDS  or  neutropenia.  There  is  extensive  skin  involvement  
and   it  requires  systemic  antimicrobial  therapy. 
             It  also  causes  irritating  folliculitis  and  a  necrotizing  skin  rash   which  
is  referred  as  jaccuzi  or  hot  tub  syndrome  that  develops  in  people  who  
uses  these  recreation  facilities. 
e)  Burn  infection:  P.  aeruginosa  is  the  most  common  cause  of  burn  wound  
infection  having  a  high  mortality  rate.  Yhey  occur  1  2  weeks  after  severe  
thermal  injury.  During  the  lag  period  the  normal  flora of  the  patients  skin  is  
replaced  by  the   hospital  flora  of  Pseudomonas  mainly  under  the  pressure  of  
antibiotics.  Sepsis  will  result  from  burn  eschar  colonization,  invasion  of  
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subeschar  space  and  invasion  of  the  bloodstream.  Systemic  symptoms  may  
occur  and  ecthyma  gangrenosum  lesions  appear  at  distant  site  from  burn  
wound   infection. Patient  may  get  pneumonia  if   any  inhalational  injury  has  
occurred. 
                                        Clinical  features  of  burn  wound  infections  are   
multifocal  discoloration of  eschar,  granulation  tissue  degeneration,  
hemorrhagic  necrosis  and  edema  of   tissue  adjacent   to  burn  site  and  brown  
to  black  neoeschar  formation.  For  successful  treatment  early   recognition  of  
wound  sepsis  by  daily   surveillance of  wound  site  focusing  on  inflammatory  
signs  and  systemic  symptoms  monitoring  is  essential.  Biopsy  including  
quantitative  culture  is  done  in  suspicious  skin  sites.  The  various  diagnostic  
features  are  presence  of  > 105  organisms  per gram  of  tissue, masses  of  
organisms  in  subeschar  space,  bacteria  in   unburned  tissue,  perivascular  
inflammation  and  hemorrhage  at  the  burn  wound  margin.                                       
           It  can also  cause  infection   of  the  nail  beds  in  people  with  artificial  
nails21. 
Urinary  Tract  Infections: 
         Urinary  tract  infections  by  Pseudomonas  are  hospital  acquired  and  
some  are  iatrogenic. The  predisposing  factors  of  UTI  are  catheterization,  by  
introducing  instruments,  by  irrigating  solutions,  surgery  including  renal  
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transplantation, persistent  sites  of  infection ( like  chronic  prostatitis  or  stones 
),  obstruction  or  previous  antibiotic  therapy.  Chronic  Pseudomonas  urinary  
tract  infections  and  recurrences  are  commonly  seen  and  they  are  
complicated  by  multidrug  resistant  Pseudomonas 
Pseudomonas  aeruginosa  in  patients  with  AIDS: 
                          P. aeruginosa  infection  are  noted  in  people  with  
advanced  stage  of  Acquired   Immunodeficiency  Syndrome.  The  
immunological  factors  like  loss  of  mucosal  integrity,  defects  in  
humoral  and   cellular  immunity,  leukocyte  abnormalities  render  the  
HIV  infected  patients  more  vulnerable   to  life  threatening  P. aeruginosa  
infection.  Mostly  they  occur  in  patients  with  low  CD4   count  and  with  
history  of  opportunistic  infections.  These  infections  occur  either  in  
presence  or  absence  of  risk  factors  for  development  of  Pseudomonas  
infections  like  previous  antibiotic  therapy,  hospitalization,  indwelling  
vascular  catheter  and  neutropenia. 
a)  P. aeruginosa  bronchopulmonary  infection  are  mostly  seen  in  late  
stages  of  HIV  infection.  Most  are  community  acquired  and  they  recur  
or  have  chronic  course  despite  proper  antibiotic  therapy. 
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b)  P. aeruginosa  bacteremia  occur  in  children  or  adults  with  AIDS.  It  
is  either  community  or  hospital  acquired,  the  primary  site  of  infection  
being  lung,  ear,  upper  respiratory  tract  or  indwelling  vascular  catheters.  
The  bacteremic  infection  are  associated  with  skin  manifestations,  sepsis  
signs  and  may  be  fatal  in  children. 
c)  Paranasal  sinus  infection  is  a  common  complication  in  advanced  
HIV  disease.  It  is  community  acquired  and  can  recur  or  have  chronic  
course.  Multiple  sinuses  may  be  invoved. 
d)  Other  AIDS  associated  Pseudomonas  infection  involve  skin,  soft  
tissue,  urinary  tract,  bones.  Malignant  otitis  externa  not  associated  with  
diabetes  mellitus  also  are  reported. 
BACTERIOCIN  PRODUCTION: 
     The  bacteriocin  of  Pseudomonas  aeruginosa  are  called  aeruginocin  or  
more  commonly  pyocins  named  after  the  former  species P. pyocyanaea.  
About  90%  of  the  P. aeruginosa  strains  has  the  ability  to  produce  pyocin  
which   is  called  Pyocinogeny.  There  are  four  distinct  types  of  pyocins. 
1)   R  pyocin -  Resembles  the  tails  of   contractile   phages. 
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2)  F  pyocin  -  Resembles  the  tail  of  non contractile  phages. It  is  flexuous,  
morphologically  distinct  rod  shaped. 
3)   S  pyocin  -   Low  molecular  weight, Trypsin  sensitive.   
4)  S  pyocin  -   Low  molecular  weight, Trypsin  resistant.  
                 There  are  a  variety  of  individual  pyocins  within  each  category  of  
pyocin  which  can  be  recognized  based  on  their  spectrum  of  activity  against  
the  different  strains  of  P.aeruginosa.  To  their  own  pyocin  ,the  strains  are  
immune  but  following  attachment  of  pyocin  to  specific  receptors  upon  the  
cell  surface ,the  sensitive  cells  are  killed.  More  than  one  category  of  pyocin  
is  produced  by  individual  strains  of  P.  aeruginosa  and  it  also  possess 
receptors   for  several  different  pyocins. 
PYOCIN  TYPING 
               In  1978,  Govan  described  the  standard  procedure,  cross  streaking  
technique.  In   this  method,  the  test  strain  is  detected  by  inhibitory   activity  
against  13  standard  indicator  strains  of  P.aeruginosa. But  this  method  has  
the  following  disadvantages: the  need  to  remove  producer  strain  growth,  the  
72  hr  time  required  for  the  result,  the  difficulty  in  typing  mucoid  strains  of  
P.aeruginosa,  the  poor  recognition  of  S  Pyocin  activity .  Fyfe,  Harris  and  
Govan  in  1984  developed  a new  revised  spotting  procedure  which  uses  the  
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same  typing  pattern  and  retains  the  same   13  indicator  strains.  The  
procedure  is  described  below. 
1)  The  strains  of  P.aeruginosa  to  be  typed  are  grown  on  Nutrient  agar  at  
37 º C  overnight.  Individual  colonies  of  each  strain  to  be  tested  are  used  in   
the  preparation  of  108  109  organism  in  1  ml  of  physiological  saline  which  
is  sterile. 
2)   Multipoint  inoculator  is  used   (which  incorporates 21  stainless  steel  pins  
suspensions   onto  13  plates  arranged  in  a  set (each  plate  with  a  diameter  of  
90  mm)  which  contains  10  ml  Trptone  Soya  Agar.  By  this  way,  20  test  
strains  (one  pin  being  a  marker)  are  able  to  be  typed  simultaneously  against  
each  indicator  strain.  The  plates  are  incubated  after  the  spots  are  dried  at    
30 º  C  for  6  hrs. 
3)  The  filter  paper  discs (5cm,  Whatman)   are  impregnated  with   chloroform  
upon  which  the  plates  are  placed  for  about  15  minutes  so  that  the  vapour  
from  the  chloroform  will  kill  the  bacteria.  The  plate  is  exposed  to  air  for  
about  15  minutes  so  as  to  eliminate  the  residual  chloroform   vapour. 
4) Cultures  of  the  indicator  strains  are  prepared  in  Nutrient  Broth  without  
agitation  at  37 º C  for  about  4  hours to  a  population  size  of  107 organisms  
per  ml. 
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5)  Separate  indicator  strain  is   applied  to  each   plate  by   adding  about  0.1  
ml  of  each  bacterial  indicator  culture  to  2.5  ml  of  molten  semisolid  
agar(1% Peptone  in  0.5% agar held  at  45 º C);  then  it  is  poured  as  an  
overlay.  The  plates  are  incubated  after  the  overlay  is  set  at  37 º C for  8  
hours. 
6)  The  pyocin  types  of  the  test  strains  are  determined  similar  to  cross  
streaking  method,  based  on   the  patterns  of  inhibition  observed  against  the  
13  indicator  strains.  But  with  the  revised  technique,  the  inhibition  zone  
sizes   are  also  taken  into  account  for  more  detailed  strain  comparison.  S  
pyocin  activity  determination  is  incorporated  into  the  typing  results  similar  
to  cross  streaking  method22. 
ANTIPSEUDOMONAL  ANTIBIOTICS: 
Carbapenems: 
                    This  belongs  to  a  group  of   betalactum  antibiotics   which  
are  obtained  by  the  modification  of  Thienamycin,  the  parent  antibiotic.  
From  the  bacteria  Sreptomyces  cattleya  thienamycin  is  derived. The  
mechanism  of  action  of   carbapenems  is  by  cell  wall  synthesis  
inhibition.  They  are  bactericidal.  They  are  not  active  against  MRSA  
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and  Enterococcus  fecium.  Bind  to  PBP1  and  PBP2  of   gram  positive 
and  gram  negative  bacteria,  causing  cell  elongation  and  lysis14.  
IMIPENEM:  It  is  highly  active  against  P.  aeruginosa  in  addition  to  
Gram  negative  aerobes,  Gram  positive  aerobes  and  many  anaerobes.  It  
is  not  active  against  Chlamydia  and  Mycoplasma  species.  It  is  
administered  parenterally  as  it  is  not  absorbed  orally.  It  is  ineffective   
against  intracellular  organisms  as  it  cannot  penetrate  intracellularly.  
The  concentration  of  the  active  drug  is  more  in  plasma  than  the  
kidney  because  it  is  hydrolysed  by  dehydropeptidase  in  the  kidney.  So  
this  drug  is  combined  with  cilastatin  which  inhinits  dehydropeptidase  
and  it  doesnot  have  anti-microbial  activity.  Dosage:  500  mg  i.m. 8  12  
hrly  or  1 - 2 g  i.v.  in  3  4 divided  doses. 
Meropenem:  It  is  a  dimethyl  carbamoyl  derivative  of  thienamycin.  It  
does  not  require  cilastatin  as  it  is  not  susceptible to dipeptidase.  It  is  
similar  to  imipenem  in  its  antibiotic  spectrum23. 
Cephalosporins: 
    These  are  isolated  from  the  fungus  Cephalosporium  acremonium. 
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   Mechanism  of   action:  It  inhibits  the  cell  wall  synthesis  and  are    
bactericidal.  There  is  increasing  resistance  to  cephalosporins   by  
betalactamases  or   by  lack  of  bacterial  permeability  to  the  drug.  There  
occurs  cross  resistance  to  other  betalactum  agents. 
                        Third  generation  cephalosporins  possess  antipseudomonal  
activity.  They  have  better  CNS  penetration  than  the  first and  second 
generation  drugs.  Fourth  generation  cephalosporins:  Cefipime  has  
similar  properties  as  third  generation  cephalosporins  but  to  some  
betalactamases  it  is  more  resistant  than  third  generation  cephalosporins.                    
Monobactums: 
Aztreonam:  It  is  a  monobactum  belonging  to  the  class of  betalactum  
antibiotics. Azreonam binds to PBP3(Penicillin Binding Protein 3) of gram 
negative aerobes,there by disrupting bacterial cell wall synthesis. They  are  
active  against  Gram  negative  bacilli  and  inactive  against  Gram  positive  
bacteria  or  anaerobes. They  are  resistant  to  the  action  of  
metallobetalactamases. It  is  given  intravenously.  The  patients  who  are  
allergic  to  penicillin  will  tolerate  aztreonam  without  any  reaction. 
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Aminoglycosides: 
Aminoglycoside  is  included  as  an  empirical  regimen  for  sepsis  caused  
by  P.aeruginosa24.  Tobramycin: It  is  also  available   in  ophthalmic  
solutions  and  ointments . 
-lactamase Inhibitors: 
1. Clavulanic acid:  It  acts  as  a  suicide  inhibitor  by  forming  an  
irreversible  acyl  enzyme  complex  with  betalactamase,  leading  to  loss  
of activity  of  the  enzyme.  Plasmid  mediated  TEM  betalactamases  
present in  Ceftazidime  resistant  strains  of  K. pneumoniae  and  E. coli  
are  inactivated  but  inducible  betalactamase (chromosomal class I) of 
Enterobacter  and  Pseudomonas  species  are  not  inhibited  by  this  drug.  
2.Sulbactam: It  is  an  effective  inhibitor  of  certain  plasmid  mediated 
and  chromosomally  mediated  betalactamases  of  S. aureus  and  many 
Enterobacteriaceae25 . 
3.Tazobactam:  It  is  suicidal  betalactamase  inhibitor  and  binds  to 
bacterial  PBP1 and  PBP2. It  remains  inactive  against  the  class  1 
betalactamase  of  Enterobacter  species,  Pseudomonas  species, S. 
maltophila and  some  Klebsiella  species. 
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BETALACTAMASES: 
Introduction-  
Even  before  Penicillin   was  used  in  medical  practice,  the  first 
betalactamase was  identified  in  E. coli. Betalactamase  production  
remains  the  most  important  contributing  factor  for  betalactam  
resistance  in  gram  negative  bacteria26. 
Key  Dates   in   Betalactamase emergence: 
Year   Enzyme  Organism  Place  
1944  Pencillinase  S. aureus  -  
1963  TEM-1  E. coli  Athens  
1974  SHV-1  E. coli  Switzerland  
1978  OXA-10  P. aeruginosa  -  
1988  Metallobetalactamase  P. aeruginosa  Japan  
1991  OXA-14  P. aeruginosa  Turkey  
1991  PER-1  P.aeruginosa,           
S. typhimurium  
Turkey  
 
METALLOBETALACTAMASE(MBL)  
                     The  first  MBL  was  reported  in  the  1960s  from  Bacillus  
cereus  and  thereafter  eighteen  MBLs  are  observed  in  various  Gram-
negative  bacteria.  These  MBLs  production  is  mostly  chromosome   
encoded  which  did  not  cause  an  obvious  threat  of  spreading  to  other  
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bacteria. However  the  first  plasmid  mediated  MBL  was  isolated  in  
1991  from  Pseudomonas  aeruginosa  and  was  reported  from  Japan 
which  was  named  as  IMP-1,  while  VIM-1,  an  another  type  of  
acquired  metallobetalactamase,  was  first  reported  in  1999  from  Italy.  
Characteristics  of  metallobetalactamase (MBL): 
1. Metallobetalactamase  requires  zinc  for  their  catalytic  activity.  
2. Their  activity  is  inhibited  by  metal  chelators  such  as  EDTA  and     
THIOL  compounds.  
3. Metallobetalactamase  in   medical   practice  hydrolyse  all  betalactam   
antibiotics  including  Penicillins,  Cephalosporins  and  Carbapenems  with 
exception  of  Aztreonam (Monobactam).  
4. MBL  producing  strains  are  not  susceptible  to  serine  betalactamase  
inhibitors (eg - clavulunate)27.   
Classification of MBL  
1.  According  to  Ambler  Molecular  classification - MBL  belongs  to 
class  B.  On  the  basis  of  their  sequences,  Class  B  is  again  divided  
into  3  subgroups  which  is  class  B1  to  B3.  
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1. Class B1:  These  enzymes  posses  the  zinc  coordinating  residues  of   
one  cysteine  and  three  histidines  and  also  will  include  the  transferable  
MBLs.  
2. Class B2:  These  enzymes  will  posess  an  asparginase  at  the   first  
position  instead  of  Histidine  in  the  principal  zinc-binding  motif.  They      
derive  from  the  Serratia  fonticola  enzyme  SFH- 1  and  Aeromonas  
species.  
3. Class-B3:  MBL  L1  is  the  sole  occupant  of  this  class,  functionally 
represented  as  a  tetramer28.  
2. According to Bush-Jacoby-Medeirois (functional) Classification:     
MBL  belong  to  group  3.  
              On  the  basis  of  Imipenem  and  other  betalactam  antibiotic  
hydrolyzing  capacity,  Group-3  is  again  divided  into  3  subgroups  which  
include,  
a. Group  3a - broad  spectrum  activity.  
b. Group  3b  preferential  activity  towards  Carbapenem.  
c. Group  3c - hydrolyse Carbapenem  poorly, as  compared  to  other 
betalactam  antibiotics29.  
3.  According  to  MBL  gene  location:  
a. Chromosomally  encoded  MBLs  
 48 
 
b. Transferable  MBLs  ( MBL  gene  as  a  part  of  integron  structure).  
4.  According  to  molecular  classification:  
Transferable MBL is divided into 4 groups-  
a. IMP(Imipenemase)Types  
b. VIM(Verona Imipenemase)Types  
c. GIM(German Imipenemase)Types  
d. SPM(Sao Paulo Imipenemase)Types30.  
TRANSFERABLE  MBLs:  
Genetic  Apparatus  Of  Transferable  MBLs 
                           Genes  encoding IMP-,  VIM-type  as  well  as  GIM-1  are  
found  as  gene  cassettes  in  class  1  integrons31.  The  VIM  and  IMP  type  
of MBLs  are  the  most  common32,33. Although  IMP  MBL   genes  are  
also  found  on  class  3  integrons.  Integrons  are  capable  of  procuring  
gene  cassettes  via  a  site-specific  recombination  event  between  two  
DNA  sites, one  in  the  integron  and  one  in  the  gene   cassette. Integrons  
gene,  its  adjacent  recombination  site,  and  a  promoter,   which  facilitates  
expression  of  the  procured  gene  cassettes  in  the variable  r
conserved  region  often  consists  of  a  partially   deleted qac gene,  fused  
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to  a  sul  gene  and  correspondingly,  confers resistance  to  antiseptics  and  
sulfonamide,  respectively. 
Gene  cassettes  are  small  pieces  of  circular  DNA,  
comprising  a  single   gene  together  with  a  recombination  site  termed  a  
59-base  element,   approximately  1 kb  in  size.  blaVIM  genes  from  
some  European   countries  have  been  found  with  a  truncated  59-base  
eleme
instances,  this  involves  the  MBL  gene  and  an  aacA4  gene  that  
encodes  kanamycin,   neomycin,  amikacin  and  streptomycin  resistance.  
Therefore,  both   aminoglycosides  and  betalactams  will  select  clinical  
bacteria27  harboring  this  fused  gene  cassette,  further  compromising  
these  antibiotic  regimens.  
               While  gene  cassettes  carrying  aminoglycoside  and  betalactam  
resistance  genes  can  freely  move  from  one  integron  to  another,  they 
cannot  by  themselves  move  from  one  organism  to  another  and  require  
the  assistance  of  other  genetic  elements  such  as  plasmids  and 
transposons. The  majority  of  MBL  genes  are  found  on  plasmids  
usually  between  120  and  180  kb.  Not  all  MBL  genes  are  associated 
with  integrons  or  transposons. The  genetic  context  of  blaSPM-1  was 
shown  to  be  unique,  being  adjacent  to  genes  closely  related  to 
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Salmonella  enteric  serovar  Typhimurium  and  not  associated  with  an   
integron  or  transposon28.  
BIOCHEMISTRY OF MBLs 
                     MBLs  and  serine  betalactamase  cleaves  the  amide  bond  of  
the  betalactam  ring  and  thus  mediate  resistance  to  betalactams; 
however,  the  way  in  which  the  two  groups  of  enzymes  achieve  this 
differs  considerably.  MBLs  possess  a  distinct  set  of  amino  acids  that   
define  the  finite  architecture  of  the  active  site  which  coordinates  the   
zinc  ions.  The  zinc  ions  in  turn  usually  coordinate  two  water   
molecules  necessary  for  hydrolysis.  The  principal  zinc-binding  motif  is 
histidine-X- histidine-X-aspartic acid (HXHXD),  which  is  common  to 
most  MBLs  apart  from  the  class  B2  enzymes.  Without  exception,  the 
preferred  metal  is  zinc,  and  while  most  MBLs  accommodate  two  zinc 
ions  in  their  active  site,  the  class  B2  enzymes  possess  just  a  single 
zinc  ion.  The  proposed  mechanism  of  hydrolysis  suggests  that  the 
active  site  orients  and  polarizes  the  betalactam  bond  to  facilitate 
nucleophilic  attack  by  zinc-bound  water / hydroxides34.  
            The  MBL  mechanism  of  hydrolysis  is  complex  and  
varies  from  one   MBL  to  another.  MBLs  may  share  less  than  25%  
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fold  and  their  active   site  architecture  is  virtually  superimposable. 
It  appears  that  most  MBLs  have  a  loop  that  is  flexible  
and this  is  thought  to  facilitate  binding  and  hydrolysis  of  the  
betalactam substrates.  MBLs  possess  a  wide  plastic  active-site  groove  
and   accordingly  can  accommodate  most  betalactam  substrates,  
facilitating their  very  broad  spectrum  of  activity.  They  are  also  
impervious  to  the   impeding  effects  of  serine  inhibitors  such  as  
clavulanic  acid  and sulbactum  that  are  often  treated  as  poor  substrates.  
Interestingly,  none of  the  MBLs  hydrolyze  aztreonam  particularly  well,  
and  it  has  been   speculated  that  it  could  be  considered  a  therapeutic  
MBL  inhibitor.  Unfortunately,  there  are  no  standardized  phenotypic  
methods  available   and  the  testing  criteria  are  likely  to  depend  on  
whether  the  gene  is   carried  by  P. aeruginosa  or  a  member  of  the  
Enterobacteriaceae, i.e.,  the  invincible  level  of  resistance.  For  example,  
most  Enterobacteriaceae   and  some  Acinetobacter  spp. Carrying  MBL  
genes  will  appear  37 sensitive,  with  Imipenem  MICs  of  between  1  and  
MBLs,  as  has  been advocated  for  extended-spectrum  betalactamases,  
must  take  account  of   the  genus  of  the  bacterium,  i.e.,  Pseudomonas  
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intrinsically  have  higher carbapenem  MICs  than  Enterobacteriaceae. It  is  
plausible  that  for screening  Enterobacteriaceae.  
                                  The  identification  of  some  betalactamases  has  been 
aided  by  isoelectric  focusing  with  the  aid  of  counterstaining  the  gel 
with  the  chromogenic  substrate  nitrocefin  to  determine  the  enzyme's 
isoelectric  point.  This  technique  is  based  on  the  surface  charge 
properties  of  these  enzymes,  which  are  neutralized  at  a  certain  pH. . 
For  closely  related  enzymes  e.g.,TEM  and  SHV,  the  isoelectric  point 
represents  a  valuable  tool  in  the  identification  process. However,  
MBLs,  even  the  transferable  types, differ  considerably  from  one 
another,  and  thus, isoelectric  focusing  is  not  recommended  as  a  tool  to 
identify  them,  although  it  can  provide  useful  information  as  to  the 
isoelectric  point  of  unknown  MBLs  by  using  EDTA  inhibition 
(preincubated  with  the  enzyme  prior  to  electrophoresis  or  soaking  the 
gel  with  EDTA  after  electrophoresis)  as  part  of  the  isoelectric  
focusing  process. Given  the  fact  that  all  MBLs  are  affected  by  the 
removal  of  zinc  from  the  active  site,  in  principle,  their  detection 
should  be  straightforward,  and  studies  have  seized  upon  this  principle 
and  used  a  variety  of  inhibitor  betalactam  combinations  to  detect 
strains  possessing  these  clinically  important  enzymes. However, MBLs 
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vary  in  their  level  of  inhibition  with  certain  compounds  and  also  vary 
in  their  ability  to  confer  resistance  to  ceftazidime  or  imipenem,  two 
substrates  commonly  used  in  screening  MBLs35.       
Risk  factors  for  MBL  colonization36  
1. Prolonged  hospital  stay  especially  in  ICU.  
2. Irrational  use  of  mulpitle  antibiotics.  
3. Patients  on  multiple  invasive  devices.  
4. Presence  of  focal  or  generalized  infection.  
Phenotypic  Methods  of  MBL  detection37  
             Screening  for  MBL  production  was  done  in  Meropenem  
resistant  isolates  by  the  following  tests:  Epsilometer  or  E  test,  
Modified  Hodge  test,  Combined  disc  test  with  meropenem  as  well  as  
ceftazidime  disc,  Double  Disc  Synergy  Test, EDTA  Disc  Potentiation  
using  four  cephalosporins. 
                  The  unique  problem  with  MBLs  is  their  unrivalled  broad  
spectrum resistance  profile.  In  addition,  in  many  cases  the  MBL  genes  
may  be located  on  plasmids  with  genes  encoding  other  antibiotic  
resistance determinants,  i.e.  aminoglycoside  resistance  genes.  These  
MBL-positive strains are usually resistant to betalactams, aminoglycosides, 
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and fluoroquinolones.  However,  they  usually remain  susceptible  to 
polymyxins.  
                   No  extended  survey  with  a  series  of  human  infections  with  
MBL-positive  isolates  has  been  performed  to  determine  the  optimal 
treatment.  Thus,  suitable  therapy  for  treating  those infections  remains 
unknown. Using  an  animal  model  of  pneumonia  infection  with  a  VIM-
2- positive  P. aeruginosa isolate, it  was  shown  that  aztreonam  at  a  high 
dose  reduced  the  bacterial  load  and  may  be  a  useful  drug.  
              The  only  therapeutic  alternative  may  be  the  therapeutic  
administration of  polymyxins,  which  have  recently  been  shown  to  be  
efficient  for  treating  multidrug-resistant  gram-negative  bacilli. It  has  
been  claimed recently  that  polymyxins  are  not  as  toxic  as  previously  
thought.  In  any  case,  these  molecules  should  not  be  used  in  
monotherapy  and rapid  determination  of  MICs  of  aminoglycosides  by  
MIC  methods  (not disk  diffusion)  may  help  to  choose  an  
aminoglycoside  molecule  that may  have  kept  some  activity.  In  addition,  
Rifampicin  may  be  an interesting  agent  for  treating  multidrug  resistant  
P. aeruginosa  infections.  
                      Clearly,  in  the  absence  of  novel  agents  in  the  near  future,  
the  spread of  MBL  producers  may  lead  to  therapeutic  dead  ends.  Early  
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detection may  avoid  spread  of  these  multidrug-resistant  isolates  and  
may  help maintain  first  and second  line  therapies.  
INDIAN  STUDIES  on  prevalence  of  P.aeruginosa  infections  and 
MBL  prevalence  and  their  detection :  
                               Shampa  Anupurba  et  al 38 (2006)  isolated  301  strains  
of  P. aeruginosa from  940  relevant  clinical  specimens  accounting  for  
32%  of  various clinical  specimens.  She  showed  that  P. aeruginosa  were  
isolated   higher  in  the  age  group  of  16 - 40  years.  Surgery  ward   has  
the  highest  prevalence  rate (29.9%)  with  antimicrobial susceptibity  for  
Cefaperazone/Sulbactum (74%)  followed  by  Ciprofloxacin (58%) and  
Ceftazidime (54%)  and   18%  of  isolates  shows  resistane  to  all  the  
eight  antibiotics.   
                     Behera  B  et  al37 (2008)  detected  Metallobetalactamase  in  
P. aeruginosa  nosocomial  isolates  by  four  different  phenotypic  methods. 
91  P. aeruginosa  samples  were  subjected  to  antibiotic  susceptibility  
testing  by  Vitek-2  and  Disc  diffusion  assay.  By   three  methods  
Imipenem  resistance  was  determined (Disk  diffusion,  Vitek-2 and  E-
test).  MBL  production  was  detected  by  the  following  screening  tests  
by  combined  disc   test  with  Imipenem-EDTA,  MBL  E  test  with  
Imipenem-EDTA  and  EDTA  disc   potentiation  test  using  four  
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Cephalosporins.  Out  of  63  isolates  which  were  resistant  to  Imipenem,  
in  56  isolates  MBL  screening  was  done.  Among   56  isolates,  36  were  
MBL  positive  by  Double  Disc  synergy  test  and  48  were  MBL  
positive  by  Combined  disc  test. E  test  was  done  in  30  isolates  to 
confirm  MBL  production.  All  30  isolates  showed  positivity  by  MBL  E  
test.  EDTA   disc  potentiation  with  four  Cephalosporins  was  not    
useful  for  MBL  detection. 
                        Ami  varaiya  et  al39 (2008)  found  that  out  of  240  
isolates,  60 (25%) were   Carbapenem   resistant   and  50 (20.8%) were  
observed  to  be  MBL producers.  Among  50  MBL  patients,  38 (76%)  
were  Diabetic  patients  and 12 (24%)  were found  to  be  cancer  patients.  
                              Noyal  et  al40  (2009)  employed  Modified  Hodge  test, 
EDTA  disc synergy  test  to  demonstrate   MBL  production  in  32  
Meropenem resistant  P.aeruginosa. 16 (50%)  were  MBL  producers  by  
EDS  test  but only  9  positive  for  Carbapenemase  by  MHT  and  finally  
observed  that EDTA  disc  synergy  is  more  sensitive  for  detetion  of  
MBL  than  MHT.  They  stated  that  both  EDTA-Meropenem  and  EDTA  
Ceftazidime combination  must  be  used  in  order  to  detect  all  MBL  
producers. 
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                           Attal  Ro  et  al36 (2010) conducted  study  with  total  140  
P. aeruginosa  strains isolated  from  various  clinical  samples. Antibiotic 
susceptibility testing with  antipseudomonal  was  done  as  per  CLSI  
guidelines. Imipenem resistant  isolates  were  screened  for  carbapenem  
hydrolysis  by  the Hodge  test  and  the  modified  Hodge  test.  MBL  
production  was  detected by DDST and Disk potentiation test. Out of 140 P. 
aeruginosa, 18(12.9%)  were  Imipenem  resistant.  Among  these  
16(88.8%)  were Hodge  test  and  modified  Hodge  test  positive  and  all  
16  were  found  to be  MBL  producers  by  the  DDST  and  disk  
potentiation  tests.  He  concluded  that  detection  of  MBL  producing  P. 
aeruginosa  strains  by  the  Disk  potentiation  test  should  be  introduced  
in  any  clinical  microbiology  laboratory  in  order  to  aid  in  infection  
control.  
                      Manoharan A  et  al41 (2010)  evaluated  the  Combined  disc  
diffusion  test (CDDT)  method  for  screening  and  confirmation  of  
metallobetalactamases  with  confirmatory  E  test  and  PCR  among  
Carbapenem  resistant  P. aeruginosa  isolates  collected  as  a  part  of  
multicentric  study (2005-2007).  CDDT  was done by using Imipenem,  
Meropenem and Ceftazidime with  EDTA.  MBL  positives  were  
confirmed  by  IMP + IMP-EDTA E  test. They reported  42.6%  to  be   
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 MBL  producers  among  61  isolates  and  15  out  of  20  MBL  producer  
strains  were  positive  strains  for  VIM  type MBL. They reported CDDT 
using IMP+EDTA had  highest  sensitivity  and specifity  of  87.8%  and  
84%  when  compared  to  E test.  CDDT  using IMP+EDTA  showed  
specifity  90.9% and sensitivity 93.3% when compared  with  PCR.  They  
recommended  routine  use  of  IMP-EDTA CDDT  test  for  screening  of  
MBL producers among Pseudomonas aeruginosa.                                                                                                      
D  Bashir  et  al42 conducted  study  with  283  P. aeruginosa isolates, 38 
(13.42%) were resistant to Imipenem. 33 (11.6%) were  found  to  be  MBL 
producers  by  combined  disk  test  and  all  of  them  showed  reduction  in 
MIC  in  the  presence  of  Imipenem-EDTA  in  E  test.  The  number  of 
MBL  positive  isolates  from  ICU  was  statistically  significant  (p=0.027).  
The  46  hospital  stay  was  significantly  longer  among  patients  infected 
with  MBL  producers  than  MBL  non  producers.           
               John  et  al43  (2011) with  the  help  of  the  following  tests                 
detected  the  presence  of  MBL  production  by  Disc  potentiation  test,  
MHT,  DDST  and  MIC  by  broth  microdilution  method.  He  observed  
MBL  positivity  in  92/331  isolates  of  Pseudomonas  aeruginosa  and  
stated  that  the  DDST  at  15mm  distance  was  more  reliable  test  than  
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CDT  and  MHT  and   the  sensitivity  was  also  good  when  zinc  sulphate  
was  dispensed  as  co-factor  for  MBL  production . 
Foreign  studies  on  detection  of  MBL  in  P. aeruginosa-  
                  Ibukun  Abinu  et  al44  (2007)  in  Nigeria  studied  occurrence  
of  ESBL  and MBL  in  P. aeruginosa  between  March  and  August  2006  
isolated  from various  clinical  specimens. ESBL  and  MBL  were  detected  
by  using double  disc  synergy  test  and  Imipenem  EDTA  combined  disc  
test respectively.  Results  showed  Carbapenems  had  highest  activity  
followed  by  Ceftazidime (79.4%).  Among  20   ceftazidime  resistant 
isolates  9  were  MBL  producers, while  4  isolates  showing  resistance  to 
carbapenems  were  ESBL  producers. Amikacin  was  most  potent  among 
Aminoglycosides and they observed high level resitance to 
Fluoroquinolones.           
                       Mohammed  Ellalib  et  al45  in  Libya  studied  the  detection  
and  prevalence  of  metallobetalactamase  in  P. aeruginosa  from  August  
2008  to  August  2009  at  Tripoli  Medical  Centre  and  Burn  and  Plastic  
Surgery  Hospital  among  312  specimens.  The  antibiotic  resistance  in  
this  study  is  Amikacin (23.1%),   Gentamicin (35.3%), Tobromycin 
(31.1%),  Cefotaxime (51%), Ceftazidime (29.5%), Cefepime (28.2%), 
Ciprofloxacin (26.9%), Imipenem (13.8%), Meropenem (15.7%), Pipercillin 
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(39.1%), Carbenicillin (51.9%), Piperacillin/tazobactam (27.6%), Ticarcillin 
(53.8%), Aztreonam (22.8%), Polymyxin B (13.8%).  Among  the  312 
isolates of P. aeruginosa, 42 ((13.8%)) were  found  resistant  to  Imipenem. 
Among  them  thirty four  Imipenem  resistant  isolates were found to be 
MBL positive (10.9%).  EDTA  disc  screen  test  is  simple  to  perform  and 
easy  to interpret and can  be  introduced  into  the  workflow  of  a  clinical 
laboratory.  
                              Eman  et  al46  studied  over  a  period  of  six  months  
from  December 2011 to May 2012  in  Alhilla  teaching  hospital,  to  study  
the  incidence  of outbreak  of  MBL  producing  P. aeruginosa  from  
various  clinical specimens.  Out  of  247  clinical  specimens  81  isolates  
were  obtained . These  isolates  were  subjected  to  susceptibility  testing  to 
anti pseudomonal  drugs  as  per  CLSI  guidelines, 32 (40%)  of  isolates  
were  carbapenem  resistant  P. aeruginosa (CRPA). They  were further  
screened  for  production  of   MBL:  by  EDTA - Imipenem  synergy  
method  and  Carbapenemase  production:  by  modified  Hodge test  and  
using  E. coli  ATCC  25922  for  control.  All (CRPA)  isolates were  MBL  
producing  isolates  and  carbapenemase  producing  isolates.                                              
 
      
  
 
 
 
 
 
 
 
 
 
 
 
MATERIALS & METHODS 
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MATERIALS  AND  METHODS 
Place  of  study 
           The  present  study  was  conducted  in  Coimbatore  Medical  
College  and  Hospital,  Coimbatore. 
Study  Period 
          The  study  period  was  conducted  for  a  period  of  one  year  from  
August  of  2013  to  July  of  2014. 
Type  of  Study 
           It  is  a  prospective  study. 
Ethical  consideration 
                Before   the  study  period,  the  Ethical  and  Research  clearance  
was  obtained  from  Ethical  Committee  of  Coimbatore  Medical  College  
and  Hospital,  Coimbatore. 
Sample 
          In  the  present  study  211  Pseudomonas  aeruginosa  were  isolated  
from  different  clinical  samples  like  pus,  urine,  blood,  aural  swab,    
wound  swab,  catheter  tip  and  sputum.             
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Inclusion Criteria 
     1)    Out  of  all  the  organisms  identified  as  Pseudomonas  aeruginosa  
the  consecutive  samples  are  included  in  the  study. 
    2)     Only  the  samples  which  show  intermediate  or  resistance  to     
meropenem  are  included   in  detection  of  metallobetalactamase  by  
phenotypic  methods. 
Exclusion Criteria 
1)  All  other  clinical   isolates  excluding  Pseudomonas  aeruginosa  
     isolated. 
PROCESSING  OF  SAMPLE: 
                                All  samples  were  collected  under  strict  aseptic  
precautions  under  standard  procedures  and  processed  under standard  
procedures. 
1) Direct  Gram  stain:    
                                       Direct  smears  with  gram  stain  was  done  to  look  
for  the  presence  of  pus  cells  and  presence  of  bacteria.  Gram  stain  
shows  plenty  of  pus  cells  with  Gram  negative  bacilli. 
2)  For  all  the  samples  except  blood,  the  samples  were  inoculated  into  
the  MacConkey  agar  and  Blood  agar  and  incubated  for  18  24  hours  
at  37 º C. 
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3)  For  blood  and  catheter  tip  culture,  BHI  broth  is  used  in   which  the  
samples  were  inoculated  and  they  are  kept  in  incubator at  37 º C for  48  
hours.  The  broth  was  examined  for  turbidity  regularly  and  subculture  
was  done  on  Blood  Agar  plate  as  well  as  MacConkey  Agar   at  
regular  intervals.  Any  growth  was  further  processed  for  identification. 
4)  The  non  lactose  fermenting  colonies  on  MacConkey  agar  which  
was  oxidase  positive  were  being  further  processed  for  identification.  
BIOCHEMICAL  REACTIONS: 
                    The  non  lactose  colonies  are  subjected  to  the  following  set  
of   tests  at  first. 
1.  Gram  Stain 
2.  Motility. 
3.  Catalase  Test. 
4.  Oxidase  Tests. 
         If  the  organism  is   a  gram  negative  bacilli,  motile,  catalase  test  
positive,  Oxidase  test  positive,  then  it  is  subjected   to   the  following  
group  of  reactions.   
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S.No Biochemical  tests Results 
1  Indole  test. Negative 
2   Positive 
3   Negative 
4   Alkaline  slant / No 
change 
5  Arginine  Dihydrolase  Test. Positive 
6  Nitrate   reduction  tests. Positive 
7  Glucose  Oxidation  tests. Oxidative  utilization. 
 
 
CATALASE TEST: 
  
Principle: 
                   The  principle  of  this  test  is  to  identify  the  presence  of  
catalase.  This  enzyme  catalyses  the  reaction  in  which  oxygen  is  
released  from  Hydrogen  peroxide.  
Procedure: 
          One  or  two  colonies  to  be  tested  is  picked  up  by  the  glass  rod  
which  must  be   sterile. It  is  inserted  into  3%  hydrogen  peroxide  kept  
in  a  sterile  glass  tube.  
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Interpretation: 
                         Presence  of  effervescence  or  gas  bubbles  formation 
immediately  or  within  seconds  will  indicate  the  positive  catalase  test  
and  no  bubble  formation  immediately  will  be  reported  as  negative  
catalase  test47.  
OXIDASE TEST: 
Principle: 
                 This  test  identifies  the  presence  of  Cytochrome  oxidase   
enzyme  in  the  bacteria.  It  catalyses  the  reaction  in  which   oxygen  
oxidizes  the  reduced  cytochrome  enzyme. 
Procedure: 
                       Filter  paper  strips  soaked  in  the  oxidase  reagent  ( 1% 
tetramethyl  para  phenylene  diamine  hydrochloride)  is  placed  in  a 
petridish  and  the  colony  to  be  tested  is  smeared  on  the  strips  using 
sterile  glass  rod.  
Interpretation: 
                           Development  of  purple  colour  within  10  sec  is 
interpreted  as  positive.  
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NITRATE TEST:  
Principle: 
                This  test  detects  the  nitrate  reductase  enzyme  present  in  the  
bacteria  which  reduces  nitrate  to  nitrite.  
Procedure: 
                     Organism  is  grown  in  5ml  of  nitrate  broth  for  24  to  48 
hours.  Equal  volumes  of  A  and  B  are  mixed  just  before  use.  0.1 ml  
of  the  reagent  mixture  is  added  to  the  culture.  
Interpretation:  
                          Development  of  red  colour  within  few  minutes  is 
considered  positive.  
Indole test  
Principle: 
                 This  test  identifies  the  presence  of  enzyme  tryptophanase  in  
the  bacteria.  This  enzyme  degrades  the  tryptophan  to  Indole.  
Interpretation:  
                         A  pink  colour  ring  development  indicates  a  positive  
test.  
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Urease test:  
Principle: 
              By  this  test  we  identify  the  presence  of  urease  enzyme.  This  
urease  can  split  urea  to  ammonia  and  Carbon dioxide .  
Procedure: 
                   
urease  medium and  incubated  for  24  48  hours  at  37  º C .  
Interpretation: 
                         Development  of  pink  colour  in  the  slope  is  interpreted 
as  positive  test.  
Citrate test  
Principle: 
                   In  this  test  we  are  testing  the  ability  of  organism  to  use  
citrate  as  the  sole  source  of  carbon .  
Procedure: 
                  
medium  and  incubated  at  37  º C   for  24  48  hours.  
Interpretation: 
                       Development  of  blue  colour  in  the  medium  is  interpreted 
as  positive.  
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Kligler Iron  agar  test  (KIA  agar):  
       KIA  agar  medium  contains  10  parts  lactose, 1  part  glucose  and 
peptone. Phenol  red  and  Ferrous  sulphate  serve  as  indicators  of  
acidification  and  hydrogen  sulphide  respectively. With  straight  
inoculation  wire,  touch  the  top  of  well  isolated  colony.  Inoculate  KIA 
by  first  stabbing  through  the  centre  of  the  medium  to  the  bottom  of  
the  tube  and  then  streaking  the  surface  of  agar  slant.  Incubate  the  
tube  at  37 º C  in  ambient  air  for  18  24  hours.  
Results:  
Alkaline slant / no change in butt ( K / NC ):  Glucose  and  lactose  non   
utilisers.  
Alkaline  slant / acid  butt ( K / A ):  Glucose fermentation only.  
Acid  slant / acid  butt ( A / A ): Glucose  and  lactose  fermenter.  
                                               A  black  precipitate  in  the  butt  indicates  
production  of  ferrous  sulphate  and  hydrogen  sulphide  gas.  Bubbles  or  
cracks  in  the  tube  indicate  the  production  of  CO2  or  H2S.  
Arginine  dihydrolase  test: 
  
                           Dissolve  the  Arginine  dihydrolase  medium  in  water  
and  adjust  pH  to  6.0.  This  is  the  basal  medium  used  as  control  and  
to  this  add  1%  L-Arginine  dihydrochloride  to  make  it  test  medium.  
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The  medium  is  purple  in  colour  as  the  indicator  is  bromocresol  
purple.  Both  the  test  tubes  are  covered  with  mineral  oil  to  give  an  
anaerobic  environment.  After  adding  the turbid  peptone  water  of  the  
test  organism  it  is  incubated  at  37 º C  for  48  hours  . 
Results:   
              The  medium  turns  to  yellow  in between  and  then  reverts  back  
to  purple  colour.  This   indicates  that  this  test  is  positive.   
SUGAR  FERMENTATION  TESTS: 
   Principle:   
                          To  demonstrate  the   ability  of  the  organisms  to  ferment  
specific  sugars  incorporated  within  the  medium  producing  acid  and  
gas. 
   Procedure: 
                           The  media  contains   peptone  water  with  1%  sugars  
(Glucose, Lactose, Sucrose, Maltose, Mannitol, etc.)  along  with  an  
media,  0.5 ml  of  the  0.5 McFarland  standard  of  the  organism  to  be  
tested  is  inoculated  into  the  sugar  media  and  it  is  incubated  for  16 - 
18  hours  at  37 º C.    
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Interpretation: 
                            The  blue  colour  of the  medium  turns  yellow  with  acid  
production   by  bacteria   and  production  of   gas  is  indicated  with  gas  
 
ANTIOBIOTIC SUSCEPTIBILITY TESTING: 
                   The  antibiotic  susceptibility  testing  for  P. aeruginosa  isolates 
was  done  by  Kirby  Bauer  Disc  Diffusion  method  as  given  in  CLSI  
guidelines.  In  the  present  study  susceptibility  was  tested  against  
following  antibiotics  obtained  commercially  from  Hi-media  laboratories  
Limited,  Mumbai.  For  control  we  used  P. aeruginosa  ATCC  27853  
strain.  The  diameter  of  the  zone  was  measured  and  interpreted  as  
sensitive,  intermediate,  resistance  according  to   the     CLSI  guidelines48. 
Antibiotic discs Concentration 
 
Sensitive 
zone in mm 
Intermediate 
zone in mm 
Resistance 
zone in mm 
Amikacin(Ak) 30 >17 15-16 <14 
Gentamicin(G) 10 >15 13-14 <12 
Ciprofloxacin(Cip) 5 >21 16-20 <15 
Ofloxacin(Of) 5 >16 13-15 <12 
Ceftazidime(Caz) 30 >18 15-17 <14 
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Cefaperazone 
Sulbactum(Cfs) 
75/30 27  33   
Cefipime(Cpm ) 30 >18 15-17 <14 
Tobramycin(Tob) 10 >15 13-14 <12 
Piperacillin 
Tazobactum(Pit) 
100/10 >21 15 - 20 <14 
Meropenem(Mrp) 10 >19 16-18 <15 
Aztreonam(Azm) 30 >22 16-21 <15 
 
The  Meropenem  resistant  isolates  are  subjected  to  the  following  four  
different  phenotypic  tests   to  detect  thr  production  of  
metallobetalactamases. 
PHENOTYPIC  METHODS  TO  DETECT 
METALLOBETALACTAMASE: 
1) MODIFIED HODGE TEST: 
                  The  Modified  Hodge  test (MHT)  was  originally  described  by  
CDC (Centre for Disease Control, Atlanta)  for  Carbapenemases  detection 
in Enterobacteriaceae. But  in  this  study I  have  included  this test for 
Metallobetalactamase  detection  in  P. aeruginosa.  
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Procedure: 
              E.coli  ATCC  
25922  is  prepared  in  5  ml  of  peptone  water.  Then  1:10 dilution  is  
of  peptone  water.   This  is  used  to  make  a  lawn culture  on  a  Mueller  
Hinton  agar  plate  and  allowed  to  dry  for  about  3 -
Meropenem  disc  was  placed  in  the  centre  of  the  plate.  Then one  
particular  P. aeruginosa  isolate  were  streaked  from  edge  of  the  disc  to  
the  periphery  of  the  plate  in  a  straight  line  using  a  0.5 mm  loop  in  
four   different  directions  like  a  cross.  In  this  test  four  different  isolates  
can  be  tested  in  a  single  plate  also. 
Interpretation  of  Results:  
         The  plate  is  examined  after  incubating  for  16 24  hours  at  
37 º C,  for  a  clover  leaf  like  indentation  which  is  seen  at  the  
intersection  of  the organism  which  is  tested  and  the  E. coli  25922.  It  
is  also  seen  within  the  inhibition  zone  of  the  meropenem  susceptibility  
disc.  
        MHT Positive  test  has  the  indentation  of   the   E.coli  25922  in  the  
shape  of  a  clover  leaf.  It  grows  along  the  test  organism  growth  streak  
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and  within  the  disc  diffusion  zone. A  positive  MHT  indicates  
carbapenemase  production  by  that  particular  isolate.  
        MHT Negative  test  has  no  growth  of  the  E.coli  25922  within  the  
disc  diffusion  as  well  as  along  the  test  organism  growth  streak.  A  
negative  MHT  indicates  carbapenemase  is  not  produced  by  that  isolate. 
2)  MEROPENEM EDTA  COMBINED  DISC  TEST (CDT):                       
                                We  performed  the  Meropenem  EDTA  combined  disc  
test  as  described  in  the  study  by  Yong  et al 49 .  The  0.5 M  EDTA  
solution  was  prepared  by  dissolving  18.61 g  of  EDTA  in  100 ml  of  
distilled  water  and  pH  was  adjusted  by  using  sodium  hydroxide  to  8.  
The  prepared  solution  was  sterilized  by  autoclaving. The  organisms  to  
be  tested  were  inoculated  on  to  Mueller  Hinton  agar  plates  according  
to  the  CLSI  guidelines.  Then  we  placed  two  meropenem  discs (Hi  
EDTA  solution  were  added  to  one  meropenem  disc  with  the  help  of  a  
were  incubated  for  16  to  18 hours  at  37 º C  and  the  inhibition  zones  
of  the  Meropenem  with  EDTA  disc  and  Meropenem  were  compared. 
zone  size  around  Meropenem  with  EDTA  disc  than  the  Meropenem  
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disc  alone,  then  the  test  is  positive.  It  indicates  that  the  test  organism  
produces  metallobetalactamase  enzymes. 
3) MEROPENEM  EDTA  DOUBLE  DISC  SYNERGY  TEST ( DDST): 
                          The  double  disc  synergy  test  of  Meropenem  and  EDTA  
was  done  as  described  in  the  study  by  Lee  et  al 50 .  The  organism  to  
be  tested  were  inoculated  on  to  the  Mueller  Hinton  agar  plate  as  per  
MHA  plate  at  a  distance  of  20  mm  centre  to  centre  from  the  blank  
concentration. The  MHA  plate  is  then  incubated  at  37 º C  for  a  
duration  of  16  to 18  hours.   If   there  was  enhancement  in  the  
inhibition  zone  of  > 5  mm  in  the  area  between  Meropenem  disc  and  
the  EDTA  disc,  then  the  test  is  positive  which  identifies  the  test  
organism  as  a  metallobetalactamase  producer. 
4) Epsilometer  or  E  TEST:  Meropenem  with  &  without  EDTA  Ezy  
MIC  Strips:  
 
(Meropenem + EDTA: 1-64 mcg / ml) 
(Meropenem : 4- 256 mcg / ml) 
                                It  is  a  unique  Phenotypic  MBL  detection   test  
which  contains  a  strip  which  is  coated  with  mixture  of  Meropenem + 
EDTA  and  Meropenem  on  a  single  strip  in  a  concentration  gradient  
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manner. It  is  procured  from  high  media  laboratories.  The  upper  half  
has  Meropenem  +  EDTA  with  highest  concentration  tapering  
downwards,  whereas  lower  half  is  similarly  coated  with  Meropenem  in  
a  concentration  gradient  in  reverse  direction. 
Test Procedure 
1. At  first  0.5  Mcfarland  standard  of  the  P.  aeruginosa  isolate  to  be   
tested  is   prepared  by  inoculating  two  to  three  colonies  onto  peptone  
water  and  incubating  it  for  2 -  3  hours  at  37 º  C. 
 2. Then  a  cotton  swab  which  is  sterile  attached  on  a  wooden  stick  is  
dipped  into  the  0.5  McFarland  standard  inoculums.  The  swab  which  is  
soaked  is  firmly  rotated  against  the  inside  wall  in  the  upper  part  of  
the  tube  to  express  excess   fluid.  With  the  help  of  the  swab  the  
whole  plate  on  its  agar  surface  is  streaked  three  times  with  the  swab,  
rotating  at  an  angle  of  60 º C  in  between  each  streaking. 
3.  Ezy  MIC  strip  is  removed  from  the  container  from  cold  and  it  is  
kept  at  room  temperature  for  15  minutes  before  opening.  Then  it  is  
applied  on   to  the  centre  of  the  MHA  plate  with  the  help  of  a  
wooden   stick. 
4.  The  MHA  plate  is  incubated  at  37 º C  for  18  -  24  hours  and  then  
the  following  values   are  observed. 
a.  MIC  of  Meropenem 
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b.  Concentration  of  MRP +  EDTA. 
c.  Ratio  of  MRP / MRP +EDTA 
Interpretation  of  E  Test: 
MBL  POSITIVE  
STRAIN: 
 
 
 
 
 
 
 
 
 
When the ratio of the value obtained for 
Meropenem  (MRP) : the value of 
Meropenem + EDTA (MRP+EDTA) is 
more than to 8  
                            or 
If zone is observed on the  side  coated  
with Meropenem+EDTA & no zone is 
observed on the opposite the side coated 
with Meropenem, interpret the culture as 
MBL positive. 
MBL  NEGATIVE  
STRAIN: 
 
 
 
 
When the ratio of the value obtained for 
Meropenem (MRP): the value of 
Meropenem+EDTA (MRP+EDTA) is less 
than or equal to 8 
MBL (NON 
DETERMINATIVE) 
 
 
 
 
 
When no zone of inhibition is obtained on 
either side. In such cases resistance may be 
due to mechanisms other than MBL 
production. These have to be further 
investigated before reporting. 
                                   or 
If the zones obtained are below the lowest 
concentration on both the sides, the strain 
has to be tested with concentrations below 
the lowest concentration on the strips 
before reaching to any conclusion. 
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QUALITY CONTROL: 
 
Quality  control  of  Ezy  MIC  Strips  is  carried  out  by  testing  the  strips 
with  standard  ATCC  Cultures  recommended  by  CLSI  on  suitable 
medium  incubated  appropriately. 
                        
Organism  Medium used  Incubation  Standard 
Pseudomonas 
aeruginosa 
ATCC 27853 
Mueller Hinton 
Agar 
35-37°C 
for 18 hrs 
When the ratio of the value 
obtained for Meropenem 
(MRP) : the value of 
Meropenem + EDTA ( MRP 
+ EDTA) is less than or equal 
to 8. 
                              
 
 
 
 
 
 
 
 
 
  
Fig. i:  MacConkey  Agar Plate showing Pseudomonas  aeruginosa 
Fig. ii:  Blood Agar  Plate  showing Pseudomonas  aeruginosa 
  
 
  
Fig. iii:  Nutrient  Agar  Plate  showing  Pseudomonas  aeruginosa 
Fig. iv:  Biochemical  reactions  of  Pseudomonas  aeroginosa 
   
Fig. v:  Sugar Fermentation Test showing Glucose Oxidation 
Fig. vi:  Moeller’s  Decarboxylase (LAO) Test 
  
Fig. vii:  AST  Plate  showing  Meropenem Resistance 
Fig. viii:  AST  Plate showing Meropenem Sensitivity 
  
  
Fig. ix: E Test Positive 
Fig. x: E Test Negative 
 
Fig. xi:  Combined Disc Test Positive 
Fig. xii:  Combined Disc Test Negative 
 
Meropenem 
with  EDTA 
Meropenem 
with  EDTA 
  
Fig. xiii: Double Disc Synergy Test Positive 
Fig. xiv: Double Disc Synergy Test Negative 
 
EDTA  
impregnated 
disc 
EDTA  
impregnated 
disc 
   
Fig. xv:  Modified Hodge Test Positive  
Fig. xvi:  Modified Hodge Test Negative  
 
  
 
 
 
 
 
 
 
Fig. xvii: AST Plate showing Ceftazidime  and  
Cefaperazone sulbactum resistance 
Ceftazidime   
Cefaperazone  
sulbactum  
  
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
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RESULTS 
 
                        In  the  present  study  211  Pseudomonas  aeruginosa  
isolates  from  various  clinical  samples  like  pus,  urine,  wound  swabs,  
sputum,  burns  were  taken  from  211  patients  during  August  2013 to  
July 2014  at  Coimbatore  Medical  College  and  Hospital,  Coimbatore.  
These  isolates  were  studied  for  detection  of  Metallobetalacamase  
production  and  their  antibiogram. 
                        The  antibiotic  susceptibility  of  P. aeruginosa  isolates 
indicated  the  following  rates  of sensitivity:  Amikacin (67.77%),  
Gentamicin (63.98%), Ciprofloxacin (53.55%),  Ceftazidime (28.91%),  
Cefoperazone  sulbactum (64.93%),  Cefipime  (70.14%),  Piperacillin + 
tazobactum (81.04%), Tobramycin (64.93%),  Meropenem (92.42%),  
Aztreonam (76.78%)  which is shown in table  1.  Among  the                      
P. aeruginosa  isolates  from  urine  Ofloxacin  showed  76.2%,  Norfloxacin  
showed  28.57%  sensitivity  and  Nitrofurantoin  were  80.95%  resistant. 
                            In  this  study ,  out   of  211 isolates,  16 (7.58%)  were  
found  to  be  Meropenem  resistant  by  disc  diffusion  method  as  seen  in  
table - 2 . 
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                                  The  MIC  of   Meropenem  among  different  MBL  
producing  P.  aeruginosa  isolates  are  in  the  range  of  24  
observed  in  table - 3.   
                   The  percentage  of MBL  detected  among  MRP  resistant  P.  
aeruginosa  isolates  are  93.75 %  by  MRP / MRP+EDTA  E  test,  81.25 %  
by  Double  Disc  Synergy  Test,  81.25 %  by  Combined  Disc  Test,  75 %  
by  Modified  Hodge  Test .  This  is  visualised  in  Table - 4. 
                               In  table  -  5,  the  2 × 2 table  shows  the  comparison  of  
the  combined  disc  method  with  E  test . Test  validity  parameters  were  
calculated  from  the  table.  The sensitivity,  positive  predictive  value  and  
accuracy  of  Combined  Disc  Test  were  found  to  be  86.67 %,  100 %  
and  87.5 %  respectively. 
                                In  table - 6,  the  2 × 2 table  shows  the  comparison  of  
the  double  disc  synergy  method  with  E  test.  Test  validity  parameters  
were  calculated  from  the  table. The   sensitivity,  positive  predictive  
value  and  accuracy  of  Double   Disc   Synergy  Test  were  found  to  be  
86.67 %,  100 %  and  87.5 %  respectively. 
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                               In  table - 7,  the  2 × 2 table  shows  the  comparison  of  
the  Modified  Hodge  test  with  E  test.  Test  validity  parameters  were  
calculated  from  the  table. The  sensitivity,  positive  predictive  value  and  
accuracy  of  Modified  Hodge  Test  were  found  to  be  80 %,  100 %  and  
97.5 %  respectively.   
                   In  table - 8,  the  2 × 2 table  shows  the  comparison  of  the  E  
test  with  MBL  producers  and  Non MBL producers.  The  sensitivity,  
specificity,  positive  predictive  value,  Negative  predictive  value  and  
accuracy  of   E  Test  were  found  to  be  100 %,  100 %,  100 %,  100 %  
and  100 %  respectively.   
                                              As  from  the  Table - 9  the  Metallobetalactamase  
prevalence  among  total  P.  aeruginosa  isolates  in  our  study  is  7.11%.   
The  Metallobetalactamase  prevalence  among  Meropenem  Resistant  
isolates  in  our  study  is  95.5 %.  This   is  shown  in  table - 10. 
                                       In  our  study,  from  the  table - 11  we  observed  that  the  
cases  are  distributed  in  the  following  age  groups:  0 - 10  years(14.22 %) 
11  20  years(6.64 %) ,  21  30  years (12.32 %) ,  31  40  years( 13.27 %) 
41  50  years(14.22 %),  51  60  years (15.64 %)  and   above  60  years  
(23.69 %) .  MBL  producing  isolates  are  seen  in  the  age  group  of  > 60  
years.   
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                            The  sex   wise  distribution  of  cases  according  to  table - 12  
are:  males - 143(67.77%)  amd  females - 68 (32.23%).  The  male : female  
sex  ratio  is  2.1 :  1 . Among  MBL  isolates,  9 (60%)  are  males  and  6 
(40%)  are   females.  The  male  female  sex  ratio  is  3 : 2 . 
                               Males  are  more   commonly   distributed  among  the  above  
40  years  age  group  about  54.44%;  while  females  are  51.46%  among  
among  the  above  40  years  age  group  according  to  table - 13.      
                              Among  the  isolates  199 (94.3%) were  from  inpatients  and  2 
(5.69%)  were  from  outpatient  department. Similarly  in  MBL  producers  
93.33% were  isolated  from  inpatient  department (IPD).  Only 6.67 %  
were  isolated  from  outpatient  department.  This  is  seen   in  table - 14. 
                                    In  our  study,  the  distribution  of  isolates  from  different  
wards  as  observed  in  table  15  are  from  Surgery 66 (31.28%), 48 
(22.75%)  from  Orthopaedics,  35 (16.59%)  from  General  Medicine, 
214(11.37% )  from  Paediatrics  and  medicine  ICUs, 11 ( 5.21%)  from  
OPD, Others  from  Nephrology,  Urology,  ENT,  Burns  and  Skin  wards.  
Among  MBL  producers  6(40%)   were  from  surgery, 4 (26.67%)  were  
from  Orthopaedics, 2 (13.33%)  from  burns  ward, 1 (6.67%)  each  from  
OG  and  Urology  ward. 
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                In  this  study,  P. aeruginosa  were  isolated  from  the  clinical  
samples as  follows:  131 (62.09%)  isolates  among  211  were  from  pus,  
30  (14.22%)  from  sputum,  21 (9.95%)  from  urine, 18 (8.54%)  from  
Blood, 5 (2.37%)  from  Ear  discharge,  4(1.9%)  from  Burns  ward  and  1 
(0.47%) each  from  Catheter  Tip  and  ET  Tube.  Out  of  6  MBL 
producers  11 (73.33%) were  from  pus,  2 (13.33%)  from  burn  ward  and  
1 (6.67%)  each  from  Urine  and  catheter  tip.   These  are  shown  in  
Table - 16.  
                                     In  the  present  study,  Pseudomonas aeruginosa 
isolates were obtained from cases of Cellulitis [19.9%],  followed  by  
traumatic  wound  infections [18.47%], cases  of  diabetic  foot  ulcers 
[16.59%], Pneumonia [14.22%], Urinary  tract  infections [8.54%], Fever  
cases [5.69%], Septicemia [5.21%], Necrotising  Fascitis [4.27%], Post  
operative  wound  infections  [2.84%],  CSOM  [2.37%],  Burns  cases 
[1.9%]  as  seen  in  table - 17.  Among  MBL  producers  the  isolates  were  
obtained from  infections  of  Trauma  wound [26.67%],  Cellulitis [20%],  
Diabetic  foot ulcer [20%], Burn  wound [13.325],  urinary  tract  infections, 
Post  operative  wound infection  and  septicemia  each  constitute  6.67% . 
                           The  antibiotic  resistance  among  MBL  isolates  are  
Amikacin (66.67%), Gentamicin (73.33%), Ciprofloxacin (73.33%),  
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Ceftazidime (100%), Cefaperazone  sulbactum (100%),  Cefipime  (100%),  
Piperacillin + tazobactum (60%), Tobramycin (100%),  Meropenem (100%), 
Aztreonam (86.67%)  which  is  shown  in  table - 18.  The  urine  isolates  
are  100 %  resistant  to  Ofloxacin,  Norfloxacin   and  Nitrofurantoin. 
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TABLE  - 1:  ANTIBIOTIC  SUSCEPTIBILITY  PATTERN   OF  
PSEUDOMONAS  AERUGINOSA  ISOLATES :   
                                  
ANTIBIOTICS P. aeruginosa  Isolates ( n = 211) 
SENSITIVITY RESISTANCE 
AMIKACIN 143(67.77%) 68(32.23%) 
GENTAMICIN 135(63.98%) 76(36.02%) 
TOBRAMYCIN 137(64.93%) 74(35.07%) 
CIPROFLOXACIN 113(53.55%) 98(46.45%) 
CEFTAZIDIME   61(28.91%) 150(71.09%) 
CEFAPERAZONE 
SULBACTUM 
137(64.93%) 74(35.07%) 
CEFIPIME 148(70.14%) 63(29.86%) 
MEROPENEM 195(92.42%) 16(7.58%) 
AZTREONAM 162(76.78%) 49(23.22%) 
PIPERACILLIN 
TAZOBACTUM 
171(81.04%) 40(18.96%) 
AMONG  URINE  ISOLATES ( n = 21) 
OFLOXACIN   16(76.2%)   5(23.8%) 
NORFLOXACIN     6(28.57%) 15(71.43%) 
NITROFURANTOIN     4(19.05%) 17(80.95%) 
 
 
 
TABLE - 2     PREVALENCE  OF  MEROPENEM  RESISTANCE  
AMONG  ISOLATES 
 
TOTAL NO OF 
CASES 
NO  OF MRP  
RESISTANT  
ISOLATES 
% OF MRP 
211 16 7.58% 
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TABLE - 3    MIC  OF MEROPENEM RESISTANT ISOLATES 
MRP RESISTANT  
ISOLATE 
MIC  OF  
MRP 
MIC  
OF  
MRP 
+  
EDTA 
RATIO  OF 
MRP/ 
MRP+EDTA 
MBL  
PRODUCED 
1 >256 4 >8 YES 
2 64 1 >8 YES 
3 24 <1 >8 YES 
4 256 2 >8 YES 
5 96 1.5 >8 YES 
6 256 2 >8 YES 
7 128 4 >8 YES 
8 96 1.5 >8 YES 
9 >256 16 >8 YES 
10 64 16 < 8 NO 
11 24 <1 >8 YES 
12 >256 2 >8 YES 
13 128 4 >8 YES 
14 48 <1 >8 YES 
15 >256 16 >8 YES 
16 128 1.5 >8 YES 
 
 
 
TABLE - 4   DETECTION  OF  MBL  BY   FOUR  DIFFERENT  
PHENOTYPIC  METHODS 
TOTAL 
MRP RES  
ISOLATES 
BY E TEST BY MHT BY CDT BY  DDST 
16 15/16(93.75%) 12/16(75%) 13/16(81.25%) 13/16(81.25%) 
 
 86 
 
TABLE - 5   COMPARISON  OF  COMBINED   DISC  TEST  WITH  E 
TEST     
 
 
COMBINED   
DISC  TEST  
        E TEST TOTAL 
POSITIVE NEGATIVE 
POSITIVE 13 0 13 
NEGATIVE 2 0 2 
TOTAL 15 0 15 
 
Sensitivity - 86.67 % 
PPV  100 % 
Accuracy  86.67% 
 
 
 
TABLE - 6   COMPARISON  OF  DOUBLE   DISC  SYNERGY TEST  
WITH  E TEST   
DOUBLE   DISC  
SYNERGY TEST 
        E TEST TOTAL 
POSITIVE NEGATIVE 
POSITIVE 13 0 13 
NEGATIVE 2 0 2 
TOTAL 15 0 15 
 
Sensitivity - 86.67 % 
PPV  100 % 
Accuracy  86.67 % 
 87 
 
TABLE - 7   COMPARISON  OF  MODIFIED  HODGE  TEST  WITH   E 
TEST 
MODIFIED  
HODGE  TEST  
        E TEST TOTAL 
POSITIVE NEGATIVE 
POSITIVE 12 0 12 
NEGATIVE 3 0 3 
TOTAL 15 0 15 
 
Sensitivity - 80% 
PPV  100 % 
Accuracy  80 % 
 
 
 
TABLE - 8   COMPARISON  OF  E TEST  AND  MBL PRODUCTION 
E TEST MBL 
PRODUCERS 
NON 
PRODUCERS 
TOTAL 
POSITIVE 15 0 15 
NEGATIVE 0 1 1 
TOTAL 15 1 16 
 
Sensitivity - 100% 
Specificity - 100 % 
PPV  100 % 
NPV  100 % 
Accuracy  100% 
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TABLE - 9  PREVALENCE  OF  MBL 
TOTAL  ISOLATES MBL DETECTED PREVALENCE  OF  MBL 
211 15 7.11% 
 
 
 
TABLE - 10   PREVALENCE  OF  MBL  AMONG  MEROPENEM  
RESISTANT  ISOLATES 
ORGANISM NO OF MRP RES ISOLATES     MBL PRODUCTION 
NO % 
P. aeruginosa 16 15 93.75 
 
 
 
TABLE - 11   AGE  WISE  DISTRIBUTION  OF  CASES 
 
AGE  
(YEARS) 
MBL NON  MBL TOTAL 
0-10 0 30 (15.31%) 30 (14.22%) 
11-20 2(13.33%) 12 (6.12%) 14 (6.64%) 
21-30 3(20%) 23 (11.73%) 26 (12.32%) 
31-40 3(20%) 25(12.76%) 28 (13.27%) 
41-50 3(20%) 27(13.78%) 30 (14.22%) 
51-60 0 33(16.84%) 33 (15.64%) 
>60 4(26.67%) 46(23.46%) 50 (23.69%) 
TOTAL 15(100%) 196(100%) 211(100%) 
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TABLE  12  SEX  WISE  DISTRIBUTION  OF  CASES 
 
SEX MBL NON  MBL TOTAL 
MALE 9(60%) 134(68.37%) 143(67.77%) 
FEMALE 6(40%) 62(31.63%) 68(32.23%) 
TOTAL 15(100%) 196(100%) 211(100%) 
 
SEX  RATIO  OF  MALE  :  FEMALE  AMONG  P. aeruginosa  is   2.1 :  1 
SEX  RATIO  OF  MALE  :  FEMALE  AMONG  MBL  isolates  is   3 : 2 
 
 
 
TABLE  13  AGE  &  SEX  WISE  DISTRIBUTION  OF  CASES 
 
AGE IN YEARS              SEX TOTAL 
MALE 
No & %  
FEMALE 
No & % 
0-10 18(12.59%) 12(17.65%) 30 (14.22%) 
11-20 9(6.29%) 5(7.35%) 14 (6.64%) 
21-30 18(12.59%) 8(11.77%) 26 (12.32%) 
31-40 20(13.99%) 8(11.77%) 28 (13.27%) 
41-50 21(14.69%) 9(13.24%) 30 (14.22%) 
51-60 28(19.58%) 5(7.34%) 33 (15.64%) 
61-70 10(6.99%) 14(20.59%) 24 (11.37%) 
71-80 16(11.19%) 7(10.29%)  23( 10.9%) 
>81 3(2.09%) 0 3 (1.42%) 
TOTAL 143(100%) 68(100%) 211(100%) 
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TABLE  - 14  INPATIENT  OUTPATIENT  DISTRIBUTION  OF  CASES 
 
TYPE MBL NON  MBL TOTAL 
INPATIENT 14(93.33%) 185(94.39%) 199 (94.31%) 
OUTPATIENT 1(6.67%) 11(5.61%) 12 (5.69%) 
TOTAL 15(100%) 196(100%) 211(100%) 
 
 
 
TABLE  15  WARD  WISE  DISTRIBUTION  OF  CASES  IN  OUR  
HOSPITAL 
 
WARD MBL NON  MBL TOTAL 
SURGERY 6(40%) 60(30.61%) 66(31.28%) 
ORTHOPAEDIC 4(26.67%) 44(22.45%) 48(22.75%) 
MEDICINE 1(6.67%) 34(17.35%) 35(16.59%) 
ICU( MED + PAED) 0 24(12.24%) 24(11.37%) 
OPD 0 11(5.61%) 11(5.21%) 
OG 1(6.67%) 8(4.08%) 9(4.27%) 
UROLOGY 1(6.67%) 5(2.55%) 6(2.84%) 
ENT 0 5(2.55%) 5(2.37%) 
BURNS 2(13.33%) 2(1.02%) 4(1.9%) 
SKIN 0 3(1.53%) 3(1.42%) 
TOTAL 15(100%) 196(100%) 211(100%) 
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TABLE  16  SAMPLE  WISE  DISTRIBUTION  OF  CASES 
SAMPLE MBL NON  MBL TOTAL 
PUS 11(73.33%) 120(61.22%) 131(62.09%) 
SPUTUM 0 30(15.31%) 30(14.22%) 
URINE 1(6.67%) 20(10.21%) 21(9.95%) 
BLOOD 0 18(9.18%) 18(8.54%) 
AURAL  SWAB 0 5(2.55%) 5(2.37%) 
BURNS WOUND 2(13.33%) 2(1.02%) 4(1.9%) 
CATHETER TIP 1(6.67%) 0 1(0.47%) 
ET TUBE 0 1(0.51%) 1(0.47%) 
TOTAL 15(100%) 196(100%) 211(100%) 
 
 
 
 
TABLE  17  INFECTIONS  CAUSED  BY  PSEUDOMONAS  
AERUGINOSA  ISOLATES 
INFECTIONS MBL NON  MBL TOTAL 
CELLULITIS 3(20%) 39(19.9%) 42(19.9%) 
TRAUMA  WOUND INFECTION 4(26.67%) 35(17.86%) 39(18.47%) 
DIABETIC  FOOT  ULCER 3(20%) 32(16.33%) 35(16.59%) 
PNEUMONIA 0 30(15.31%) 30(14.22%) 
URINARY  TRACT  INFECTION 1(6.67%) 17(8.67%) 18(8.54%) 
FEVER 0 12(6.12%) 12(5.69%) 
SEPTICEMIA 1(6.67%) 10(5.1%) 11(5.21%) 
NECROTISING   FASCITIS 0 9(4.59%) 9(4.27%) 
POST  OP 1(6.67%) 5(2.55%) 6(2.84%) 
CSOM 0 5(2.55%) 5(2.37%) 
BURNS 2(13.32%) 2(1.02%) 4(1.9%) 
TOTAL 15  (100%) 196 (100%) 211(100%) 
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TABLE  - 18 :  ANTIBIOTIC  RESISTANCE  PATTERN   OF  
METALLOBETALACTAMASE  PRODUCING  ISOLATES:   
                                  
ANTIBIOTICS             MBL  PRODUCERS ( n = 15 ) 
           NO PERCENTAGE 
AMIKACIN 10 66.67% 
GENTAMICIN 1 73.33% 
TOBRAMYCIN 15 100% 
CIPROFLOXACIN 1 73.33% 
CEFTAZIDIME 15 100% 
CEFAPERAZONE 
SULBACTUM 
15 100% 
CEFIPIME 15 100% 
MEROPENEM 15 100% 
AZTREONAM 13 86.67% 
PIPERACILLIN 
TAZOBACTUM 
9 60% 
AMONG  URINE  ISOLATES: 
OFLOXACIN 1 100% 
NORFLOXACIN 1 100% 
NITROFURANTOIN 1 100% 
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DISCUSSION 
 
                                 There  is  higher  morbidity  and  mortality  associated  
with  MBL  producing  organisms  because  of  the  fact  that  all  classes  of  
betalactam  antibiotics  will  be  hydrolysed  by  MBL.  As  we  have  not  
yet  developed  a  safe  therapeutic  antibiotic,  there  will  be  a  clinical  
disaster  if  it  spreads  continuosly.  The  presence  of  an  MBL  positive  
isolate  causes  a  therapeutic  problem  and  is  also  of  major  concern  in  
the  infection  control  management.  Because  MBL  producing  strains  are  
difficult  to  detect,  they  pose  a  serious  threat  as  it  can  spread  silently  
within  institutions.  It  also  has  the  important  role  in  horizontal  MBL  
gene  transfer  to  other  pathogens  in  the  hospital.  The  call  of  the  hour  
now  is  detection  and  containment  and  not  mere  treatment.           
               Hence  with  the  above  perspective,  the  present  study  was  
conducted  an  attempt  to  know  the  prevalence  of MBL  producing  P. 
aeruginosa  isolated  from  sputum, wound  swabs,  blood,  catheter  tip,  
urine  and  aural  swabs  and  also  their  antibiogram  at  Coimbatore  
Medical   College,  Coimbatore.  The  results  are  compared  with  other  
studies. 
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Age  wise  Distribution: 
                            In  this  study  the  predominant  age  group  is  above  60  
years  both  for  P.  aeruginosa  and  MBL  isolates.  This  is  similar  to  the  
study  by  Deeba  et  al42  and  Vinodkumar  et  al51  in  whose  studies  the  
most  common  age  group  is  more  than  60  years.   It  is  different  from  
Prabhat  et  al52  and  in  his  study  among  post  operative  wound  
infections  the  most  common  age  group  is  21 -  40  years.  Among  MBL  
isolates  the  isolates are  mostly  observed  in  the  age  group  of  above  40  
years.  This  is  also  seen  in  the  study  by  Shobha  et  al53  and  Varaiya  et  
al39.   
Sex  wise  distribution: 
                                 In  our  study  males (67.77%)  are  predominantly  
affected  than  females  among  P. aeruginosa.  This  is  similar  to   the  
study  by   Prashant  et  al54,  Rajat  et  al55  in  whose  study  64.28%  and  
61%  were  males.  In  the  study  by  Shobha53  et  al  males  are  more  
susceptible  than  females  but  with  a  higher  percentage  about  81%.  The  
male  female  ratio  in  our  study  is  2.1 : 1.  It  correlates  well   with  the  
study  by  Luqman  et  al56  and  Shampa  et  al38.  In  MBL  producers  the  
male  female  ratio  is  3 : 2.  It  is  similar  to  the  study   by  Varaiya  et  
al39  and  Shobha  et  al53.  In  our  study  males  are  commonly  affected  in  
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the  age  group  of  above  40  years.  This  is  similar  to  the  study  by  
Senthamarai  et  al57  in  whose  study  males  are  commonly  observed   
above  40  years  age  group.   
Out/In  Patient  distribution: 
                      This  study  shows  that  the  isolates  of  P.  aeruginosa  as  
well  as  MBL  isolates  are  more   frequently  distributed  among  the  
inpatients (94.31%)  than  the  outpatients.  This  correlates  well  with  the  
following  studies  by  Bogiel  et  al58,  Vikas umar  et  al59  and  Patil  et  al60   
which  showed  92.9%,  87%  and  72%  respectively. 
Ward  wise  distribution: 
                             Surgery  is  the  most  frequent  ward (31.28%)  from   
which  the  P.  aeruginosa   isolates  are  obtained  in  our  study.  This  is  
similar  to  the  study  by  Angadi  et  al61,  Rajat  et  al55  and  Deeba   et  al42  
which  showed  36%,   48%  and  60%  respectively.  Ortho  is  the  second  
most  common  ward    which  correlates  with  the  study  by  Prashant  et  
al54 .  But  it  differs  from  the  study  by  Wankhede  et  al62,  Nasrin  et  al63  
in  whose  study  ICU  is  the  most  frequent  ward  among   the  isolates  
studied.  Even  among  MBL  isolates  surgery  is  the  most  common  ward 
(40%)  which  is  similar  to  the  study  by  Sherin   et   al64,  Attal  Roa  et  
al36  and  Deeba  et  al42  which  showed  51%,  50%  and  36%.  Ortho  is  
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the  second  ward  similar  to  the  study  by  Mehul  et  al27  among  MBL  
isolates.  
Sample  Wise Distribution: 
                      In  our  study  wound  swab (62.09%)  is  the   most  common  
specimen  among  the  isolates  of  P.  aeruginosa.  This  is  also  observed  
in  the  following  studies  by  Tellis  et  al65,  Anil  Rajput  et  al7 ,  Attal  
Roa  et  al36  and  Angadi   et  al61.  But  Burns  wound  is  the  most  
frequent  specimen  obtained  by  the  study  by  ElBarky  et  al66  which  
showed  37.93%   and  Eman  et  al67 which  showed  67%;  Urine  is  the  
predominant  specimen  in  the  study by  Nutan  et  al67;  Sputum  is  
predominant  isolate  by  Sangeetha  et  al68  study.  Among  MBL  isolates  
Wound  swab  is  the  predominant  specimen (73.33%)  obtained  in  our  
study.  This  correlates  well  with  the  study  by  Ahir  et  al69,  Bhaleroa  et  
al70.  But  in  the  study  by  Bogiel  et  al58  and  Wankhede  et  al  urine  and  
in  the  study  by  Shanthi  et  al35  Respiratory  tract  specimen  are  the  
frequently  obtained  specimen  respectively  among  MBL  producers. 
Distribution  of  P.  aeruginosa  infections: 
                                   The  predominant  infections  caused  by  P.  
aeruginosa  in  our  study  are  cellulitis (19.9%),  wound  infections  caused  
by  trauma (18.47%)  and  diabetic  foot  infections ( 16.59%).  This  is  
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similar  to  the  study  by    Prashant  et  al54  which  showed  that  among  the  
infections, 19 %  were  cellulitis,  16.67 %  trauma  wound  infections,  15 %  
diabetic  foot  ulcers.  It  differs  from  the  study  by  Mehul  et  al27  in  
whose   study  predominant  infections  are  burn  wounds,  ulcers  and  
abscesses  each  constituting  25 %. 
Distribution  of  Antibiotic  Sensitivity  Pattern: 
                                   The  following  are  Pseudomonas  aeruginosa  isolates  
resistance  patterns:  Ceftazidime  is  71.09 % resistant  similar  to  the  study  
by  Ahir  et  al69,  Behera  et  al37  and  Luqman  et  al56;  Ciprofloxacin  is  
46.45%  resistant  similar  to  study  by  Eman  et  al46,  Prashant   et  al54  
and  Rajat  et  al55;  Gentamicin  is  36.02 %  and  Amikacin  is  32.23 %  
resistant  which  correlates  with  the  study  by  Senthamarai   et  al57,  
Prashant  et  al54  and  Basak  et  al71;  Tobramycin  is  35.07%  resistant  
similar  to  study  by  Mohammed  et  al45,  Sanchez  et   al72   and  Prashant  
et  al54; Cefaperazone  sulbactum  is  35.07%  similar  to   Senthamarai  et  
al57  study;  Cefipime  is  29.86 %  resistant  which  correlates  with  the  
study   by  Varaiya  et  al39,  Mohammed  et  al45  and  Prabhat  et  al52;  
Aztreonam  is  23.225  resistant  which is  similar  to  the  study  by  Zubair  
et  al73,  Mohammed  et  al45  and  Basak  et  al71;  Piperacillin  Tazobactum  
is  18.96 %  resistant similar  to  study  by  Prabhat  et  al52  and  Basak  et  
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al71.  Among  the  urine  isolates  Ofloxacin  is  23.8 %  resistant  which  
correlates  with  Senthamarai  et  al57  study;  Norfloxacin  is  71.43 %  
which  is  similar  to  the   study  by  Bhalerao  et  al70   in  which  it  is  73%  
and  Nitrofurantoin  is  81 %  resistant  which  is slightly  lower  than  the  
study  by  Bhalerao  et  al70 .  Thus  the  prevalence  and  sensitivity  pattern  
of  P. aeruginosa  can  vary  within  the  community  or  between  hospitals  
located  in  the  same  community  or  vary  between  the  patients  in  the  
same  hospital.  Hence  it  is  the  duty  of  the  physician  to  know  about  
the  prevalence  as  well  as  antibiotic  susceptibility  pattern  of  the  
frequently  encountered  organisms.   So  there  should  be  a  system  in  
each  hospital  for  the  surveillance  of  antimicrobial  resistance  which has  
to  collect  and  collaborate  the microbiological  and  clinical  data.  
Prevalence  of  MRP  Resistance: 
      Meropenem  resistance  in  our  study  is  7.58%  which  is  similar  to  
the  study  conducted  by  Moyo  et  al74,   Mehul  et  al27 ,  Basak  et  al71 
and  Attal   Roa  et  al36   which  showed  8.88%,  5%,  2.4%  and  12.9% .  
But  it  is  of  higher  values  in  the  following  study  by  Kali  et  al76,  
Buchunde  et  al77  and  Supriya  et  al78   which  may  be  due  to  the  usage  
of  broad  spectrum  antibiotics  in  large  number  to  the  patients.   In  our  
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study  the  percentage  is  less   which  signifies  that  the  broad  spectrum  
antibiotics  were  used  conservatively. 
Prevalence  of  MBL: 
                                         MBL  prevalence  among  P.  aeruginosa  isolates  
is  7.11%.  This  is  similar  to  the   study  conducted  by  Navaneeth  et  
al79,  Agarwal  et  al80,  Buchunde  et  al77.  This  prevalence  is  increased  in  
the  study  by  Vahdani  et  al81,  Oh  EJ  et  al82. The  high  
metallobetalactamase  prevalence  in  the  above  said  studies  is  due  to  the  
indiscriminate  use  of  carbapenems  in  that  part  of  the  world.  This  
prevalence  is  decreased  in  the  study  by  Wolska  et  al83.                                 
  Resistance  of  MBL  among  MRP  Resistant  isolates: 
                               In  our  study  MBL  resistance  among  MRP  resistance  
isolates  is  95%  which  is  similar  to  the  study  conducted  by  Vinod  
kumar  et  al51,  Sakshi  et  al84,  Attal  Roa  et  al36  and  Vinita  et  al85.  This  
percentage   is  decreased  in  the  study  conducted  by  Perez  et  al86,  
Samuelsen  et  al87  and  Franco  et  al88. 
MIC  of  MRP: 
    The  Minimum  Inhibitory  Concentration   of  Meropenem  resistant  
isolates  are  in  the  range  from  24  
with  the  study  by  Sherin  et  al64,  Jayakumar  et  al89  and  Deeba  et  al42. 
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Antibiotic  Resistance  pattern  among  MBL  isolates: 
                        Among  the  metallobetalactamase  producing  Pseudomonas  
aeruginosa  isolates  Ceftazidime,  Cefaperazone  sulbactum,  Cefipime,  
Tobramycin  and  Meropenem  showed  100 %  resistance.  This  correlates  
well  with  the  study  by  Varaiya  et  al39,  Deeba  et  al42,  Shoba  et   al53  
and  Attal  Roa  et  al36.  Gentamicin  and  Ciprofloxacin  showed  73.33 %  
resistance  which  is  similar  to  the  study  by  ElBarky  et  al66.  Aztreonam  
showed  86.67 %  resistance  which  is  in  accordance  with  the  study  by 
ElBarky  et  al66.  Amikacin  showed  66.67 %  resistance  which  correlates  
with  the  study  by  Sherin  et  al64.  Piperacillin  Tazobactum  showed  60 %  
resistance  which  is  similar  to  the  study  by   Sherin  et  al64  and  Varaiya  
et  al39.  Among  urine  isolates  Ofloxacin,  Norfloxacin  and   
Nitrofurantoin  showed  100 %  resistance.  This  is  in  accordance  with  the  
study  by  Bhalero  et  al70,  Mouawad  et  al90  and  Deeba  et  al42  which  
showed  100 %  resistance  to  Nitrofurantoin  and  Ofloxacin. 
Detection  of  MBL  by  Phenotypic  Tests: 
                  Among  the  Meropenem  resistant  isolates,  93.75 %  of  MBL   
were  detected  by  E  test  method.  This  is  in  accordance  with  the  study  
by  Basak  et  al71,  Varsha  et  al91  and  Aktas  et  al92.  By  using  Modified  
Hodge  test  method  75  %  of  MBL  were  detected.   This  is  similar  to   
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the  study  by  Sakshi  et  al84  and  Attal  Roa  et  al36.  With  Double  Disc  
synergy  test  method  81.25 %  were  MBL  producers.  It  correlates  with  
the  study  by  Sherin  et  al64   and  Basak  et  al71.  By  using  combined  
Disc  test  method  81.25 %  were  MBL  producers.  This  corresponds  with  
the  following  study  by  Clare  et  al93,  Sangeetha  et  al68,  Behera  et  al37,  
Vikas  kumar  et  al59  and  Hemalatha  et  al75.        
Sensitivity,  Specificity,  PPV,  NPV  and  Accuracy  of  four  tests: 
                       In  our  study  Modified  Hodge  test  shows  80 %  sensitivity,  
100 %  Positive  predictive  value  and  80  %   accuracy.  But  in  the  study  
by  Tellis  et  al65  it  showed  a  sensitivity  of  74.32 % and  98.2 %  of  
PPV.  By  Combined  disc  test,  the  sensitivity,  PPV  and  Accuracy  were  
86.67 %,  100 %  and  86.67 %  respectively.  This  corresponds  to   the  
study  by  Manoharan  et  al41  and  Maria  et  al94.  But  in  the  study  by  
van der  Bij  et  al95  there  was  100 %  sensitivity  to  combined  disc  test  
and  Samuelson  et  al87  showed  29 %  of  PPV. Double  disc  synergy  test  
shows    sensitivity  of  86.67 %,  PPV  of  100 %  and  Accuracy  of  
86.67% .  This  is  similar  to  the  study  by  Tellis  et  al65  and  Clare  et  
al93.  It  is  different  from  the  study   by  Khosravi  et  al96  which  shows  
100 %  sensitivity.    
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     In  our  study  E  test  showed  accurate  results  with  excellent  
sensitivity  and  specificity.  This  correlates  with  the  study  by  Timothy  
et  al97  and  Davies  et  al98.  Both  DDST  and  CDT  are  the  better  tests  
than  Modified  Hodge  test  in  our  study.  This  is  similar  to  the  studies  
by  Jesudason  et  al99,  Yan  et  al100  and  Lee  et  al50  which  states  that  
Double  Disc  Synergy  Test  is  better  than  Modified  Hodge  test.  In  the  
study  by   Sevitha  Bhat  et  al101 ,  DDST  is  a  better  test.  So  E  test  is  a  
simple  test  to  perform  as  well  as  to  interpret.  This  test  can  be  
proposed  to  the  clinical  laboratories  to  screen  for   
metallobetalactamases  in  Meropenem  resistant  P.  aeruginosa.  As  E  test  
has  high  specificity  it  can  be  used  to  detect  MBLs  in  low  prevalence  
areas  also.            
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
SUMMARY 
 103 
 
SUMMARY 
 
                            The  present  study  was  carried  out  at  Coimbatore  
Medical  College  and  Hospital,   Coimbatore  from  August  2013  -  July  
2014.  Among  the  clinical  isolates  of  Pseudomonas  aeruginosa     
obtained  from  various  samples,  antibiotic  resistance  was  found  and  
Metallobetalactamase    production  was  detected  by  four  phenotypic  
methods. 
 The  maximum  number  of  Pseudomonas  aeruginosa  isolates  are  in  the  
age  group  of  above  60  years. 
 This  study  showed   male  preponderance  with  the  male  female  ratio  of  
2.1 : 1. 
 In  our  study  the  isolates  were  mostly  obtained  from  the  inpatients. 
 Wound  swab  is  the  predominant  specimen   in  the  isolates,  in  this  
study.   
 This  study  showed  surgery  is  the  most  common  ward  from  where  
isolates  are  obtained. 
 Cellulitis  is  the  most  observed  infection  among  P. aeruginosa  isolates. 
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 Overall  Ceftazidime ( 71.09%)  is  the  most  resistant  drug  followed  by  
Ciprofloxacin (46.45%)  and  Gentamicin ( 36.02%).  Among  urine  isolates  
Nitrofurantoin  shows  81%  resistance. 
 The  MRP  Resistance  among  our  isolates  is  7.48% 
 The  Prevalence  of  Metallobetalactamase  among  P.  aeruginosa isolates  is  
7.11%. 
 Among  MRP  Resistance  isolates  95%  were  MBL producers. 
 The  MIC  of MRP  resistant  isolates  is  in  the  range   of  24  - 256   
 
 Among  the  four  phenotypic  tests  the  maximum  sensitivity  of  100 %  
and  the  maximum  specificity  of  100 %  was  obtained  for  E  test,  the  
maximum   positive  predictive  value  of  100 %  was  obtained  for  DDST,  
CDT,  MHT,  E  TEST   i.e.  all  the  four  phenotypic  tests.  The  maximum   
negative  predictive  value  of  100 %  was  obtained  for  E  test  and  again  
the  maximum  accuracy  of  100%  was  obtained  for  E  test  only.  
  Among  the  phenotypic  tests  E  Test  is  the  test  by  which  maximum  
number  of  MBL  producers  were  detected.   
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 The  MBL  isolates  are  predominantly  seen  in  the  age  group  of  above  
40  years. 
 Among  MBL  isolates  males  are  more  frequently  affected.  Male  female  
ratio is  3 : 2 . 
 From  surgery  ward  MBL  producers  are  commonly  isolated. 
 Among  MBL  producers  73.33 %  were  pus  swabs,  13.33%  were  from  
burn  wounds. 
 Cellulitis  is  often  encountered  in  MBL producers. 
 The  antibiotics  which  are  100 %  resistant  in  MBL  producers  are  
Tobramycin,  Ceftazidime,  Cefaperazone  sulbactum,  Cefepime  and  
Meropenem.  Among  urine  isolates  100 %  resistance  was  obtained  for  
Ofloxacin,  Norfloxacin  and  Nitrofurantoin. 
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CONCLUSION 
            
                          Among  hospital  isolates  of  P. aeruginosa,  Metallo 
betalactamase  producing  organisms  are  becoming  a  significant  problem.  
There  is  increased  prevalence  of  ESBL  producing  organisms  in  the  
hospitals  nowdays  and  the  carbapenem  usage  is  also  increased  which  
leads  to  the  problem  of  increased  MBL  production. In  this  era,  the  
emergence  of  Metallobetalactamase  has  led  to  the  requirement  of  strict  
statuatory  guidelines  to  intervene  and  limit  the  inappropriate  use  of  
antibiotics.    
                            The  following  are  the  possible  factors  which  leads  to  
unnecessary  antimicrobial  usage.  i)  No  guidelines  to  implement  the  
rational  antibiotic  prescribing  principle.  ii)  Ignorance  of  the  rise  in  
multidrug resistant  organisms  which  is  an  alarming  problem  now. iii)  
Promotion  of  pharmaceutical   products.  iv)  Infection  control  is  
inadequate  and  it  further  compounds  the  problem. 
                             As  we  have  to  monitor  these  emerging  resistant  
determinants  in  large  scale,  we  are  in  the  need  to  develop  a  simple  
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screening   test  designed  to  detect  MBL  production.  There  are  various  
screening  methods  recommended  to  detect  MBL  production.    
                                           In  our  study  95 %  of  MRP  resistant  isolates  
are  MBL  producers  by  E  test  method.  Still  some  other  resistance  
mechanisms  like  permeability  mutation  or  porin  loss  or  upregulation  of  
efflux  systems  can  be  missed  by  the  E test.  If  we  detect  MBL  
producing  P. aeruginosa  isolates  earlier,  appropriate  antimicrobial  
therapy  can  be  provided  to  the  patient  and  thereby  we  can  avoid  the  
development  as  well  as  dissemination  of  these  multidrug  resistant  
strains.  There  is  very  few  development  of  newer  antibiotics  and  it  also  
takes  more  time  to  be  available  commercially.  The  only  alternative  left  
is  stringent  infection  control  plus  antibiotic  stewardship  program  which  
limits  the  spread  of  metallobetalactamase  producing  organisms  by  
using  the  available  antimicrobial  armamentarium.  
                        In  our  country  the  hospitals  are  woefully  inadequate  in  
proper   implementation  of  hospital  control  policies.  Proper  disinfection  
practices  can  reduce  infection.  Antibiotics  are   prescribed  as  a  
prophylactic  measure  during  the  postoperative   period. Even  after  the  
antibiotics  are  administered  for  the  required  period,  many  times  the  
stop  signals  are  not  given. 
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                                        Detection  of  genes  which  code  for  
metallobetalactamase  production  by  PCR  gives  satisfactory  and  reliable  
results.  But  because  of  the  cost  this  method  is  of  limited  practical  
value  in  clinical  laboratory  for  daily  use. 
                      So  E  test,  a  simple  and  inexpensive  method  must  be  
introduced  in  every  clinical  microbiological  laboratory in  order  to  aid    
in  infection  control.  In  case  of  very  small  laboratories  in  whom  E  
Test  itself  is  costlier,  they  can  use  Combined  disc  test  or  Double  disc  
synergy  test  to  detect  MBL  production. 
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viii) KEY  TO  MASTER  CHART 
M Male 
F Female 
Mch Male  child 
Fch Female   child 
SUR Surgery 
MED Medicine 
OPD Out  Patient  Department 
ORTHO Orthopaedics 
PAED ICU Paediatric  Intensive   Care   Unit 
NICU Neonatal  Intensive   Care   Unit 
IMCU Intensive   Medical  Care   Unit 
S Sensitive 
R Resistant 
P Positive 
N Negative 
BK Below  Knee 
AK Above  Knee  
RTA Road  Traffic   Accident 
CRF Chronic  Renal  Failure 
MRM Modified  Radical  Mastoidectomy 
Post op Post  Operative 
SSG Split  Skin  Graft 
COPD Chronic  Obstructive  Pulmonary  Disease 
#BB Fracture  Both   Bones 
LRI Lower  Respiratory  tract  Infections 
HT Hypertension 
Ak Amikacin 
Gen Gentamicin 
Tob Tobramycin 
Cip Ciprofloxacin 
Caz Ceftazidime 
Cfs Cefaperazone Sulbactum 
Cpm Cefipime 
Mrp Meropenem 
Atm Aztreonam 
Pit Piperacillin Tazobactum 
Of Ofloxacin 
Nx Norfloxacin 
Nit Nitrofurantoin 
 
                                           
